var title_f7_34_7712="Sectoral disc swelling";
var content_f7_34_7712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior sectoral pale disc swelling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superior sectoral pale disc swelling in an ischemic optic neuropathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7712=[""].join("\n");
var outline_f7_34_7712=null;
var title_f7_34_7713="Difluprednate: International drug information";
var content_f7_34_7713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Difluprednate: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Epitopic (FR);",
"     </li>",
"     <li>",
"      Myser (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of corticosteroid responsive dermatoses",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Topical: Apply twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: 0.02% (40 g); 0.05% (15 g)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10367 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-A2ED1F3088-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7713=[""].join("\n");
var outline_f7_34_7713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323398\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978545\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978548\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978544\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821237\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978547\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/16/20739?source=related_link\">",
"      Difluprednate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/60/10180?source=related_link\">",
"      Difluprednate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_34_7714="Pelvic lymphadenectomy1";
var content_f7_34_7714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unsheath external iliac artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7714=[""].join("\n");
var outline_f7_34_7714=null;
var title_f7_34_7715="Granular casts";
var content_f7_34_7715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Granular and waxy casts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing waxy and fine and coarse (arrow) granular casts. The broader casts are thought to form when there is stasis (due to advanced renal failure) in the wider collecting tubules into which many nephrons drain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7715=[""].join("\n");
var outline_f7_34_7715=null;
var title_f7_34_7716="Beclomethasone (nasal): Pediatric drug information";
var content_f7_34_7716=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"22\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beclomethasone (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21109?source=see_link\">",
"    see \"Beclomethasone (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/51/16180?source=see_link\">",
"    see \"Beclomethasone (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7990246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Beconase AQ&reg;;",
"     </li>",
"     <li>",
"      Qnasl&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7990247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Beclomethasone&reg;;",
"     </li>",
"     <li>",
"      Mylan-Beclo AQ;",
"     </li>",
"     <li>",
"      Nu-Beclomethasone;",
"     </li>",
"     <li>",
"      Rivanase AQ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10470857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Intranasal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10473424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21109?source=see_link\">",
"      see \"Beclomethasone (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Seasonal and perennial rhinitis, nasal polyps (Beconase&reg; AQ):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-12 years: Initial: 1 inhalation in each nostril twice daily; may increase if needed to 2 inhalations in each nostril twice daily; once symptoms are adequately controlled, decrease dose to 1 inhalation in each nostril twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children, Adolescents &ge;12 years, and Adults: 1-2 inhalations in each nostril twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7991835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, intranasal, as dipropionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qnasl&trade;: 80 mcg/inhalation (8.7 g) [contains dehydrated ethanol; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal, as dipropionate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beconase AQ&reg;: 42 mcg/inhalation (25 g) [contains benzalkonium chloride, ethanol 0.25%; 180 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7990249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10473462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake container well before use; gently blow nose to clear nasal passages before administration; occlude one nostril with finger while carefully inserting nasal applicator into other nostril to administer dose.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10473363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10470858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of seasonal or perennial rhinitis and nasal polyposis (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7991709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Growth velocity reduction in children and adolescents, HPA function suppression (dose related), weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry/irritated nose, throat and mouth, hoarseness, localized",
"     <i>",
"      Candida",
"     </i>",
"     or",
"     <i>",
"      Aspergillus",
"     </i>",
"     infection, loss of smell, loss of taste, nausea, unpleasant smell, unpleasant taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, epistaxis, localized",
"     <i>",
"      Candida",
"     </i>",
"     infection, nasal septum perforation (rare), nasal stuffiness, nosebleeds, rhinorrhea, sneezing, transient irritation, ulceration of nasal mucosa (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts (rare), glaucoma (rare), intraocular pressure increased (rare), tearing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, paradoxical bronchospasm (rare), pharyngitis, sinusitis, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions, immediate and delayed hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10472616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to beclomethasone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10472618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use beclomethasone with extreme caution in patients with respiratory tuberculosis; untreated bacterial, fungal, systemic viral or parasitic infections; or ocular herpes simplex. Localized",
"     <i>",
"      Candida",
"     </i>",
"     infections of the nose and pharynx have been reported rarely; interruption of therapy may be necessary while antifungal therapy is employed. Corticosteroids impair wound healing; avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma; allow healing to occur before use. Use of nasal beclomethasone in place of systemic corticosteroids may unmask allergies (eg, eczema, rhinitis) that were previously controlled by the systemic corticosteroids. Rare cases of immediate hypersensitivity reactions, nasal septum perforation, increased IOP, glaucoma, or cataracts may occur with intranasal corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10472617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HPA suppression or hypercorticism (Cushing's syndrome) may occur with use of higher than recommended doses or at typical doses in susceptible patients. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use, with stress, or when converting from systemic to topical corticosteroid therapy; withdrawal or discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7991686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7991687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies following SubQ administration but not with oral inhalation. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of allergic rhinitis during pregnancy (NAEPP,  2005).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10473463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check mucous membranes for signs of fungal infection. Monitor growth in pediatric patient. Monitor IOP with therapy &gt;6 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10473364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10473365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within a few days up to 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10473366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Beclomethasone dipropionate (BDP): 20 L; 17-BMP: 424 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: BDP 87%; 17-BMP: 94% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: BDP is a prodrug (inactive) which undergoes rapid hydrolysis to 17-BMP (active monoester) during absorption; BDP is also metabolized in the liver via cytochrome P450 isoenzyme CYP3A4 to 17-BMP and two other less active metabolites: Beclomethasone-21-monopropionate (21-BMP) and beclomethasone (BOH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 17-BMP: 44% (43% from swallowed portion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: BDP: 0.5 hours; 17-BMP: 2.7 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10473464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/51/16180?source=see_link\">",
"      see \"Beclomethasone (nasal): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval; may cause dry mouth; avoid spraying in eyes; avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay; discard canister when labeled number of metered doses (sprays) have been used.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10473465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aqueous beclomethasone nasal spray (42 mcg/inhalation; 2 sprays in each nostril twice daily for 4 weeks, followed by 1 spray in each nostril twice daily) may be useful in reducing adenoidal hypertrophy and nasal airway obstruction in children 5-11 years of age (Demain, 1995).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Demain JG and Goetz DW, &ldquo;Pediatric Adenoidal Hypertrophy and Nasal Airway Obstruction: Reduction With Aqueous Nasal Beclomethasone,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(3):355-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/34/7716/abstract-text/7862473/pubmed\" id=\"7862473\" target=\"_blank\">",
"        7862473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kobayashi RH, Tinkelman DG, Reese ME, et al, &ldquo;Beclomethasone Dipropionate Aqueous Nasal Spray for Seasonal Allergic Rhinitis in Children,&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1989, 62(3):205-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/34/7716/abstract-text/2646995/pubmed\" id=\"2646995\" target=\"_blank\">",
"        2646995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15947 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7716=[""].join("\n");
var outline_f7_34_7716=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990247\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10470857\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473424\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990249\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473462\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473363\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10470858\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991709\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10472616\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10472618\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10472617\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298818\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770054\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991686\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991687\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473463\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473364\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473365\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473366\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473464\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473465\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15947\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15947|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21109?source=related_link\">",
"      Beclomethasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/51/16180?source=related_link\">",
"      Beclomethasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30199?source=related_link\">",
"      Beclomethasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/17/26901?source=related_link\">",
"      Beclomethasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/13/44245?source=related_link\">",
"      Beclomethasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_34_7717="Lanreotide: Drug information";
var content_f7_34_7717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lanreotide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/35/18997?source=see_link\">",
"    see \"Lanreotide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5357701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Somatuline&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5046220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Somatuline&reg; Autogel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5046222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Somatostatin Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5053611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acromegaly:",
"     </b>",
"     Adults (per U.S. labeling)",
"     <b>",
"      or",
"     </b>",
"     Children &ge;16 years and Adults (per Canadian labeling): SubQ: 90 mg once every 4 weeks for 3 months; after initial 90 days of therapy, adjust dose based on clinical response of patient, growth hormone (GH) levels, and/or insulin-like growth factor 1 (IGF-1) levels as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GH &le;1 ng/mL, IGF-1 normal, symptoms stable: 60 mg once every 4 weeks; once stabilized on 60 mg every 4 weeks, may consider regimen of 120 mg every 6-8 weeks (extended-interval dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GH &gt;1-2.5 ng/mL, IGF-1 normal, symptoms stable: 90 mg once every 4 weeks; once stabilized on 90 mg every 4 weeks, may consider regimen of 120 mg every 6-8 weeks (extended-interval dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GH &gt;2.5 ng/mL, IGF-1 elevated and/or uncontrolled symptoms: 120 mg once every 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5053610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Acromegaly:",
"     </b>",
"     Children &ge;16 years (",
"     <i>",
"      Canadian labeling",
"     </i>",
"     ): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5053612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5357740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling",
"     </i>",
"     : Moderate-to-severe impairment: Recommended starting dose: 60 mg; use of an extended-interval dose of 120 mg every 6-8 weeks should be done with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Moderate-to-severe impairment: Recommended starting dose: 60 mg every 4 weeks for 3 months then adjust dose based on clinical response of patient, growth hormone (GH) levels, and/or insulin-like growth factor 1 (IGF-1) levels as described in adult dosing; however, extendedinterval dosing is",
"     <b>",
"      not",
"     </b>",
"     recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5357741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Moderate-to-severe impairment: Recommended starting dose: 60 mg; use of an extended-interval dose of 120 mg every 6-8 weeks should be done with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Moderate-to-severe impairment: Recommended starting dose: 60 mg every 4 weeks for 3 months then adjust dose based on clinical response of patient, growth hormone (GH) levels, and/or insulin-like growth factor 1 (IGF-1) levels as described in adult dosing; however, extended-interval dosing is",
"     <b>",
"      not",
"     </b>",
"     recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F243955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Somatuline&reg; Depot: 60 mg/0.4 mL (0.4 mL); 90 mg/0.4 mL (0.4 mL); 120 mg/0.5 mL (0.5 mL) [contains natural rubber/natural latex in packaging; volume is expressed as an approximate value]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Somatuline&reg; Autogel&reg;: 60 mg/~0.3 mL (~0.3 mL); 90 mg/~0.4 mL (~0.4 mL); 120 mg/~0.5 mL (~0.5 mL) [packaging contains natural rubber/natural latex]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5053613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by deep subcutaneous injection into superior outer quadrant of buttocks. Do not fold skin. Alternate injection sites.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F243956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term treatment of acromegaly in patients who are not candidates for or are unresponsive to surgery and/or radiotherapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5046177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lanreotide may be confused with pasireotide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Somatuline&reg; may be confused with Soma, somatropin, SUMAtriptan",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5053346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Bradycardia (5% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (26% to 65%; dose related), abdominal pain (7% to 19%; dose related), flatulence (&le;14%; dose related), nausea (11%), weight loss (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (3% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Cholelithiasis/gall bladder sludge (2% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (6% to 22%; induration 5%; pain 4%; mass 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (5%), sinus bradycardia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyper-/hypoglycemia/diabetes (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (8%), vomiting (7%), loose stools (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic skin reaction, aortic valve regurgitation, dysautonomia, injection site pruritus, mitral valve regurgitation, pancreatitis, steatorrhea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5046226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     U.S. labeling: There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to lanreotide, somatostatin (or related peptides), or any component of the formulation; complicated, untreated lithiasis of the bile ducts",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5046227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholelithiasis: May reduce gall bladder motility, leading to gall stone formation (may be dose- or duration-related); Canadian labeling recommends ultrasonography with the initiation of therapy and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyper-/hypoglycemia: Inhibition of insulin and glucagon secretion may affect glucose regulation, leading to hyper-/hypoglycemia. Carefully monitor blood glucose levels with the initiation of therapy and with dosage alterations. Use with caution in patients with diabetes; may require dosage adjustments in antidiabetic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypothyroidism: Decreases (slight) in thyroid function have been observed during therapy; may require monitoring of thyroid function tests.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiac disorders: Bradycardia, sinus bradycardia, and hypertension have been observed with therapy. Use with caution in patients with preexisting cardiac disease. Patients without preexisting cardiac disease may experience a decrease in heart rate though not to the level of bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; lower doses are recommended at therapy initiation in patients with moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; lower doses are recommended at therapy initiation in patients with moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cyclosporine: Concurrent use with cyclosporine may result in decreased serum levels of cyclosporine; monitor.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Latex: The packaging (needle cover) may contain latex.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5053352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: Somatostatin Analogs may decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Somatostatin Analogs may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5053356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Some herbal medications may enhance the hypoglycemic effect of lanreotide. Management: Avoid alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng, gymnema, marshmallow, and stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5357702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5046223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated embryocidal and teratogenic effects, as well as transitory growth retardation. Very little data exists from clinical trials and/or postmarketing reports of lanreotide in pregnancy. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only if benefits outweigh potential risks to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5046225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion into breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Somatuline Depot Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/0.2 mL (0.2 mL): $3152.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg/0.3 mL (0.3 mL): $3709.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg/0.5 mL (0.5 mL): $5028.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5053615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum GH and IGF-1 (in patients switched to extended-interval dosing; obtain initial levels 6 weeks after dose) glucose levels, thyroid function (where clinically indicated); heart rate, gall bladder ultrasonography (prior to initiation and periodically during therapy)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5053619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ipstyl (DK, IT, NO);",
"     </li>",
"     <li>",
"      Somatulina (ES);",
"     </li>",
"     <li>",
"      Somatuline (AT, BE, CL, CZ, EE, GR, HN, NL, PL, RU);",
"     </li>",
"     <li>",
"      Somatuline Autogel (AR, AU, BG, CH, CO, DE, GB, IE, IL, KP, NZ, SE);",
"     </li>",
"     <li>",
"      Somatuline LP (FR);",
"     </li>",
"     <li>",
"      Somatuline P.R. (CZ, FI, HK, IL, SG, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5053599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic octapeptide analogue of somatostatin which is a peptide inhibitor of multiple endocrine, neuroendocrine, and exocrine mechanisms. Displays a greater affinity for somatostatin type 2 (SSTR2) and type 5 (SSTR5) receptors found in pituitary gland, pancreas, and growth hormone (GH) secreting neoplasms of pituitary gland and a lesser affinity for somatostatin receptors 1, 3, and 4. Reduces GH secretion and also reduces the levels of insulin-like growth factor 1.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5053601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : ~0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 79% to 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively within GI tract after biliary excretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 69% to 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: 23-36 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Mean: 7-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&lt;1% to 5% as unchanged drug); feces (&lt;0.5% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Caron P, Beckers A, Cullen DR, et al, &ldquo;Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2002, 87(1):99-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/34/7717/abstract-text/17489310/pubmed\" id=\"17489310\" target=\"_blank\">",
"        17489310",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rasmussen E, Eriksson B, Oberg K, et al, &ldquo;Selective Effects of Somatostatin Analogs on Human Drug-Metabolizing Enzymes,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1998, 64(2):150-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/34/7717/abstract-text/9728895/pubmed\" id=\"9728895\" target=\"_blank\">",
"        9728895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reubi JC, Waser B, Schaer JC, et al, &ldquo;Somatostatin Receptor sst1-sst5 Expression in Normal and Neoplastic Human Tissues Using Receptor Autoradiography With Subtype-Selective Ligands,&rdquo;",
"      <i>",
"       Eur J Nucl Med",
"      </i>",
"      , 2001, 28(7):836-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/34/7717/abstract-text/11504080/pubmed\" id=\"11504080\" target=\"_blank\">",
"        11504080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10184 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7717=[""].join("\n");
var outline_f7_34_7717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357701\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046220\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046222\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053611\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053610\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053612\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357740\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357741\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243955\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950128\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053613\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243956\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046177\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053346\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046226\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046227\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299575\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053352\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053356\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357702\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046223\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046225\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322938\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053615\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053619\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053599\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5053601\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10184|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/35/18997?source=related_link\">",
"      Lanreotide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_34_7718="Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma";
var content_f7_34_7718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7718/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7718/contributors\">",
"     Brian Forbes, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7718/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7718/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7718/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7718/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7718/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/34/7718/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abusive head trauma (AHT) is also known as nonaccidental head injury, inflicted head injury, or inflicted childhood neurotrauma. One subset is referred to as shaken baby syndrome, with a constellation of inflicted injuries in young children characterized by repeated acceleration-deceleration injury with or without blunt head impact [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Characteristic clinical features include retinal hemorrhages (often bilateral, multilayered, and extensive), subdural hematoma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occult fractures (particularly of the ribs and long bone metaphyses). Multiple episodes of trauma may occur before the abuse is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Early recognition can be lifesaving.",
"   </p>",
"   <p>",
"    The pathogenesis of retinal hemorrhages in AHT will be reviewed here. Other aspects of AHT and the management of suspected child abuse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retina is comprised of several layers (",
"    <a class=\"graphic graphic_figure graphicRef68854 \" href=\"UTD.htm?15/58/16294\">",
"     figure 1",
"    </a>",
"    ). The retinal vessels are contained in the neural portion of the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/9\">",
"     9",
"    </a>",
"    ]. The large vessels course through the nerve fiber and ganglion cell layers. Smaller vessels are located between the nerve fiber and inner nuclear layers. There are three layers of retinal capillaries: those within the nerve fiber and ganglion cell layers, those in the inner nuclear layer, and the radial peripapillary capillaries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies demonstrate an increased rate of orbital hemorrhage in AHT victims compared with victims of unintentional (accidental) head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/10\">",
"     10",
"    </a>",
"    ]. Repetitive acceleration-deceleration (shaking) forces appear to play a primary role in the development of orbital and subdural hemorrhage in AHT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. The role of repetitive acceleration-deceleration forces in the pathogenesis of subdural hemorrhage in AHT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link&amp;anchor=H4#H4\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\", section on 'Mechanisms of injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other mechanisms have been proposed to play a role in the development of retinal hemorrhages, but none is universally accepted. Different types of retinal hemorrhages may have different mechanisms, and more than one mechanism may operate in any given instance (",
"    <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68695 \" href=\"UTD.htm?23/8/23683\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64277 \" href=\"UTD.htm?21/18/21795\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54695 \" href=\"UTD.htm?2/18/2339\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is unknown how much force is necessary in AHT for ocular injuries to occur. Based upon the frequency of the types of eye injuries in 23 AHT fatalities, one group suggested that relatively less force is needed to cause intraretinal, subhyaloid, or optic nerve sheath hematoma than retinal detachment, choroidal hemorrhage, or vitreous hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/16\">",
"     16",
"    </a>",
"    ]. However, given that these were fatal injuries, the involved forces for all injuries were likely to have been severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Repetitive acceleration-deceleration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive acceleration-deceleration (shaking) forces appear to play a primary role in the development of orbital hemorrhage in AHT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. The optic nerve and other intraorbital structures are firmly attached to the globe and to the apex of the orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the optic nerve is longer than the distance between the apex of the orbit and the back of the globe. This allows the globe and orbital contents to move if a child is shaken. Injury may occur at the tethering locations as a result of translational and rotational movements of the globe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repetitive acceleration-deceleration induces shearing forces at the vitreoretinal interface, directly damaging the retinal vessels. The shearing forces are applied to the retina at points of firm attachment (eg, the macula, retinal vessels, and peripheral retina) (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13\">",
"     13",
"    </a>",
"    ]. The high frequency of hemorrhages at the vitreous base (ie, peripheral retina) and the distinctive macular retinoschisis of AHT provide supportive evidence for the role of shaking and vitreoretinal traction in the pathogenesis of AHT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link&amp;anchor=H13#H13\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\", section on 'Retinal folds and retinoschisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repetitive acceleration-deceleration also may disrupt the autonomic supply of the retinal vessels, which may lead to retinal hemorrhage through disruption of the vascular integrity and autoregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link&amp;anchor=H16#H16\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\", section on 'Optic nerve sheath hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This mechanism of direct optic nerve injury within the orbit provides an explanation for the optic atrophy that is often seen in survivors of AHT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13\">",
"     13",
"    </a>",
"    ]. It also provides an explanation for the anterior predominance of optic nerve sheath hemorrhage (a finding that argues against the continuous tracking of blood from the intracranial space, as described below). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Intracranial bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Increased intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intracranial pressure (ICP) is another proposed mechanism for retinal hemorrhages in AHT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13\">",
"     13",
"    </a>",
"    ]. One theory postulates that increased ICP (secondary to cerebral edema and compressive subdural hemorrhage) causes increased venous pressure and obstruction in the retinal vasculature that ultimately leads to rupture of the retinal vessels. Another theory speculates that paroxysmal cough can progressively increase ICP to the point that retinal hemorrhage occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Terson syndrome is uncommon in infants and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13,15,18\">",
"     13,15,18",
"    </a>",
"    ]. In a prospective series, of 57 children with intracranial hemorrhage not caused by child abuse, only two patients (1.5 percent) had retinal hemorrhages, and both had other feasible explanations for the hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/18\">",
"     18",
"    </a>",
"    ]. The retinal hemorrhages in children not subject to AHT were superficial and confined to the posterior pole [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and differ in pattern and quantity from the retinal hemorrhages in AHT.",
"   </p>",
"   <p>",
"    Several observations argue against a major role for increased intracranial pressure in the development of retinal hemorrhages in AHT. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Branch or central retinal vein occlusion is an uncommon manifestation of AHT.",
"     </li>",
"     <li>",
"      Retinal hemorrhage is rarely seen in other causes of increased ICP, and when it is, the hemorrhages are few in number and confined to the posterior pole.",
"     </li>",
"     <li>",
"      The veins of the orbit permit extensive distribution of pressure because they do not have valves.",
"     </li>",
"     <li>",
"      The lack of correlation between signs of elevated ICP and retinal hemorrhage in AHT [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Examination of 35 infants hospitalized with pertussis and 100 other infants with severe cough due to other etiologies did not identify any patients with retinal hemorrhages [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intracranial bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of retinal or vitreous hemorrhage in association with subarachnoid hemorrhage is known as Terson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/18\">",
"     18",
"    </a>",
"    ]. In adult patients with subarachnoid hemorrhage, Terson syndrome is associated with poor prognosis. Terson syndrome merely refers to the association between vitreous and occasionally retinal hemorrhage as well as subarachnoid bleeding and does not imply a specific etiology. Thus, it should not be misconstrued as an alternative explanation for retinal hemorrhage in children with abusive head trauma (AHT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Terson syndrome is uncommon in infants and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13,15,19\">",
"     13,15,19",
"    </a>",
"    ]. In a prospective series, of 57 children with intracranial hemorrhage not caused by child abuse, only two patients (1.5 percent) had retinal hemorrhages, and both had other feasible explanations for the hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/19\">",
"     19",
"    </a>",
"    ]. The retinal hemorrhages in children not subject to AHT were superficial and confined to the posterior pole [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and differ in pattern and quantity from the retinal hemorrhages in AHT.",
"   </p>",
"   <p>",
"    The pathogenesis of Terson syndrome is not known. One theory is that blood from the intracranial space tracks along the optic nerve sheath and into the eye",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compresses the central retinal vein [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13,23\">",
"     13,23",
"    </a>",
"    ]. However, in an autopsy study of 13 infants who died of acute intracranial injuries after inflicted trauma, optic nerve sheath hemorrhage was present only in the intraorbital portion of the nerve, which argues against the continuous tracking of blood from the intracranial space [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, in a series of 75 children with AHT, there was no correlation between the laterality of intracranial bleeding and the laterality of retinal findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased intrathoracic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe and abrupt increase in intrathoracic pressure may cause intraocular abnormalities, possibly related to a sudden increase in retinal venous pressure (Purtscher retinopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/25\">",
"     25",
"    </a>",
"    ]. Classic findings are white retinal patches and a few retinal hemorrhages.",
"   </p>",
"   <p>",
"    This mechanism has been proposed for the retinal findings in AHT and is thought to be supported by the evidence of transiently increased intrathoracic pressure in victims who also have rib fractures. However, it is unlikely that abrupt increases in intrathoracic pressure account for the intraocular findings in most cases of AHT because white retinal patches are distinctly unusual in AHT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/13,24,26\">",
"     13,24,26",
"    </a>",
"    ]. In addition, not all victims of AHT have rib fractures, and among those who do, not all have retinal hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7718/abstract/5,12,27\">",
"     5,12,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abusive head trauma (AHT) describes a constellation of inflicted injuries in young children, including retinal hemorrhages, subdural hematoma,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occult fractures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The retina is composed of several layers (",
"      <a class=\"graphic graphic_figure graphicRef68854 \" href=\"UTD.htm?15/58/16294\">",
"       figure 1",
"      </a>",
"      ). The retinal vessels are contained in the neural portion of the retina. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive acceleration-deceleration (shaking) forces appear to play a primary role in the development of orbital and subdural hemorrhage in AHT. Several other mechanisms have been proposed to play a role in the development of retinal hemorrhages, but none is universally accepted. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive acceleration-deceleration induces shearing forces at the vitreoretinal interface, directly damaging the retina, retinal vessels, and the optic nerve. The primary role of repetitive acceleration-deceleration forces in AHT is supported by the frequency of peripheral hemorrhages and optic atrophy in AHT, the distinctive macular retinoschisis, and the anterior predominance of optic nerve sheath hemorrhage. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Repetitive acceleration-deceleration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other proposed mechanisms for the development of retinal hemorrhages in AHT include increased intracranial pressure, intracranial bleeding, and increased intrathoracic pressure. These mechanisms are less well supported than repetitive acceleration-deceleration. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Increased intracranial pressure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Intracranial bleeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Increased intrathoracic pressure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/1\">",
"      Mills M. Funduscopic lesions associated with mortality in shaken baby syndrome. J AAPOS 1998; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/2\">",
"      Lancon JA, Haines DE, Parent AD. Anatomy of the shaken baby syndrome. Anat Rec 1998; 253:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/3\">",
"      Caffey J. The whiplash shaken infant syndrome: manual shaking by the extremities with whiplash-induced intracranial and intraocular bleedings, linked with residual permanent brain damage and mental retardation. Pediatrics 1974; 54:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/4\">",
"      Christian CW, Block R, Committee on Child Abuse and Neglect, American Academy of Pediatrics. Abusive head trauma in infants and children. Pediatrics 2009; 123:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/5\">",
"      King WJ, MacKay M, Sirnick A, Canadian Shaken Baby Study Group. Shaken baby syndrome in Canada: clinical characteristics and outcomes of hospital cases. CMAJ 2003; 168:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/6\">",
"      Jenny C, Hymel KP, Ritzen A, et al. Analysis of missed cases of abusive head trauma. JAMA 1999; 281:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/7\">",
"      Alexander R, Crabbe L, Sato Y, et al. Serial abuse in children who are shaken. Am J Dis Child 1990; 144:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/8\">",
"      Lambert SR, Johnson TE, Hoyt CS. Optic nerve sheath and retinal hemorrhages associated with the shaken baby syndrome. Arch Ophthalmol 1986; 104:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/9\">",
"      Aryan HE, Ghosheh FR, Jandial R, Levy ML. Retinal hemorrhage and pediatric brain injury: etiology and review of the literature. J Clin Neurosci 2005; 12:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/10\">",
"      Gilliland MG, Luckenbach MW, Chenier TC. Systemic and ocular findings in 169 prospectively studied child deaths: retinal hemorrhages usually mean child abuse. Forensic Sci Int 1994; 68:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/11\">",
"      Gleckman AM, Evans RJ, Bell MD, Smith TW. Optic nerve damage in shaken baby syndrome: detection by beta-amyloid precursor protein immunohistochemistry. Arch Pathol Lab Med 2000; 124:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/12\">",
"      Morad Y, Kim YM, Armstrong DC, et al. Correlation between retinal abnormalities and intracranial abnormalities in the shaken baby syndrome. Am J Ophthalmol 2002; 134:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/13\">",
"      Levin AV. Ophthalmology of shaken baby syndrome. Neurosurg Clin N Am 2002; 13:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/14\">",
"      Sturm V, Landau K, Menke MN. Optical coherence tomography findings in Shaken Baby syndrome. Am J Ophthalmol 2008; 146:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/15\">",
"      Forbes BJ, Christian CW, Judkins AR, Kryston K. Inflicted childhood neurotrauma (shaken baby syndrome): ophthalmic findings. J Pediatr Ophthalmol Strabismus 2004; 41:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/16\">",
"      Green MA, Lieberman G, Milroy CM, Parsons MA. Ocular and cerebral trauma in non-accidental injury in infancy: underlying mechanisms and implications for paediatric practice. Br J Ophthalmol 1996; 80:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/17\">",
"      Geddes JF, Talbert DG. Paroxysmal coughing, subdural and retinal bleeding: a computer modelling approach. Neuropathol Appl Neurobiol 2006; 32:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/18\">",
"      Mills MD. Terson syndrome. Ophthalmology 1998; 105:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/19\">",
"      Schloff S, Mullaney PB, Armstrong DC, et al. Retinal findings in children with intracranial hemorrhage. Ophthalmology 2002; 109:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/20\">",
"      Shiau T, Levin AV. Retinal hemorrhages in children: the role of intracranial pressure. Arch Pediatr Adolesc Med 2012; 166:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/21\">",
"      Curcoy AI, Trenchs V, Morales M, et al. Is pertussis in infants a potential cause of retinal haemorrhages? Arch Dis Child 2012; 97:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/22\">",
"      Goldman M, Dagan Z, Yair M, et al. Severe cough and retinal hemorrhage in infants and young children. J Pediatr 2006; 148:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/23\">",
"      Brinker T, L&uuml;demann W, von Rautenfeld DB, et al. Breakdown of the meningeal barrier surrounding the intraorbital optic nerve after experimental subarachnoid hemorrhage. Am J Ophthalmol 1997; 124:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/24\">",
"      Budenz DL, Farber MG, Mirchandani HG, et al. Ocular and optic nerve hemorrhages in abused infants with intracranial injuries. Ophthalmology 1994; 101:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/25\">",
"      Tomasi LG, Rosman NP. Purtscher retinopathy in the battered child syndrome. Am J Dis Child 1975; 129:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/26\">",
"      Kivlin JD, Simons KB, Lazoritz S, Ruttum MS. Shaken baby syndrome. Ophthalmology 2000; 107:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7718/abstract/27\">",
"      Lazoritz S, Baldwin S, Kini N. The Whiplash Shaken Infant Syndrome: has Caffey's syndrome changed or have we changed his syndrome? Child Abuse Negl 1997; 21:1009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6611 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7718=[""].join("\n");
var outline_f7_34_7718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Repetitive acceleration-deceleration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Increased intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intracranial bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased intrathoracic pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6611\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6611|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/58/16294\" title=\"figure 1\">",
"      Retinal layers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/42/35497\" title=\"figure 2\">",
"      Retinal hemorrhage types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/8/23683\" title=\"figure 3\">",
"      Superficial retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/18/21795\" title=\"figure 4\">",
"      Deep retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/18/2339\" title=\"figure 5\">",
"      Preretinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2150\" title=\"figure 6\">",
"      Cross section of the eye",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_34_7719="Treatment and prognosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)";
var content_f7_34_7719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7719/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7719/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7719/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7719/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7719/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/34/7719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is a syndrome characterized by diffuse inflammation of lung parenchyma and airways in response to the inhalation of antigens to which the patient has been previously sensitized. Numerous inciting agents have been described including, but not limited to, agricultural dusts, bioaerosols, and certain reactive chemical species. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=see_link\">",
"     \"Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because both environmental and host factors are involved in the production of the HP syndromes, management theoretically can involve modification of the environment or of the host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the pathogenesis of HP is incompletely understood, and emphasis on environmental control remains the cornerstone of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevention, treatment, and prognosis of HP will be reviewed here. The diagnosis of HP is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link\">",
"     \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HP can be reduced by diminishing exposure to provocative antigens. This may be accomplished by minimizing contact with potential inciting agents, reducing microbial contamination of the work or home environment, or using protective equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Reduction of antigenic burden",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alteration in the handling and storage of potential sources of microbial antigens can diminish the occurrence of HP. As examples, dispersion of actinomycetes spores is decreased by wetting compost prior to handling, and use of antimicrobial solutions in sugar cane processing diminishes fungal growth and the development of bagassosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Design of facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indoor microbial contamination is usually related to problems with moisture control [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/3\">",
"     3",
"    </a>",
"    ]. Appropriate design of facilities may reduce stagnant water that is prone to microbial overgrowth. Thus, humidity in occupied buildings should be maintained below 60 percent, carpeting should be avoided in areas where persistent moisture is likely to be present, and water in heating, ventilating, and air conditioning systems should not be recirculated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive maintenance should be performed routinely in order to ensure that all heating, ventilation, and air conditioning equipment is properly maintained and that the indoor environment is clean. Portable humidifiers or vaporizers should be drained daily with removal of all slime, and sterilized frequently with either chlorine bleach or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All water damage should be immediately repaired because microbial colonization occurs quickly and can be very difficult to eradicate. Water-damaged furnishings, drywall, and carpeting should be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Protective devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devices which limit inhalation of inciting antigens may be useful when complete elimination of these antigens is impossible [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As an example, the level of antigen exposure occasionally can be controlled by the appropriate use of environmental controls such as an electrostatic dust filter in the return ducts of a central air conditioning system [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of various types of personal respirators in preventing antigen sensitization and disease progression is unknown. Their use is most appropriate when avoidance of the causative antigen cannot easily and rapidly be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/7\">",
"     7",
"    </a>",
"    ]. Helmet-type powered air purifying respirators have been used to prevent episodic exposure in individuals with previous acute episodes of farmer's lung, but are cumbersome to wear for prolonged periods. Dust respirators offer poor protection against organic particulates and are not useful once sensitization has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best studied forms of HP are farmer's lung and pigeon breeder's lung; treatment of other types of HP largely is extrapolated from the experiences in these populations. Antigen avoidance usually results in regression of disease, but glucocorticoid treatment may be required in more severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antigen avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of the antigens responsible for a case of HP is of critical importance in managing the index case and for preventing sensitization of other individuals. Measures to minimize ongoing antigenic exposure should be undertaken as described above.",
"   </p>",
"   <p>",
"    Complete elimination of allergen exposure sometimes is not possible without avoidance of the causative environment. Such a course may require relocation to a new job or home, but still may not guarantee improvement. We recommend that a patient with progression of disease in the context of ongoing exposure should be advised in the strongest terms to avoid the antigen by whatever means necessary. It is more difficult to determine the degree to which antigen avoidance is required when a patient has recovered completely, although possibly temporarily, from an initial episode of HP. The risk of recurrence is unclear in this setting, and drastic measures to avoid inciting antigens may not always be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/4,5,8\">",
"     4,5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Farmer's lung poses particular problems because of the emotional and financial ramifications of leaving the farm environment. While a change of employment and residence may be necessary in persons with severe disease, several studies show that most farmers with HP do not progress clinically even if they do not modify their employment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/4,5,9\">",
"     4,5,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, persons with bird fancier's lung frequently are reluctant to give up their birds. If they do, recovery is not assured because high levels of bird antigens can be detected in the home environment for prolonged periods of time after bird removal and environmental cleanup [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids appear to accelerate initial recovery from farmer's lung and bird fancier's lung, particularly in severely ill patients; however, the long-term outcome appears unchanged by glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Treatment is usually prescribed for patients with subacute or chronic disease, in particular, those patients with persistent symptoms (eg, dyspnea, cough, fatigue, weight loss), abnormal lung function tests (eg, lung restriction and reduced diffusing capacity), hypoxemia, or radiographic evidence of extensive lung involvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 93 patients with farmer's lung compared patients treated with glucocorticoids either for 4 or 12 weeks with a group of control patients treated only with antigen avoidance [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/11\">",
"       11",
"      </a>",
"      ]. Symptom resolution was more rapid among the glucocorticoid-treated groups, but no differences in the course of disease among the three groups were noted after six months. The 12 week glucocorticoid regimen offered no advantage over the four week regimen. Limitations of this report are that the nonglucocorticoid-treated group had less severe disease and the study was not blinded.",
"     </li>",
"     <li>",
"      A trial of 36 persons with acute farmer's lung randomized patients to eight weeks of treatment with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/12\">",
"       12",
"      </a>",
"      ]. After one month, there was a significant improvement in DLCO in the prednisolone-treated group, but no statistically significant differences in FVC, FEV1, or DLCO were found after that time until follow-up was terminated at five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon experience with farmer's lung and bird fancier's lung, glucocorticoids are the standard treatment for severely ill patients with all varieties of HP. Therapy is usually initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 0.5 to 1 mg per kilogram of ideal body weight per day (up to a maximum daily dose of 60 mg per day), given as a single dose each morning [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/13\">",
"     13",
"    </a>",
"    ]. This dose is maintained for one to two weeks and then tapered over the next two to four weeks. Maintenance doses are not usually required, particularly if the patient has been removed from exposure. Inhaled glucocorticoids may be effective in treating or preventing recurrence, but this approach has not been well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, problems with the use of systemic glucocorticoids. They cause a variety of side effects, and treatment is not tolerated in all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) In addition, steroid treatment may lead to an improved sense of well-being which, in some cases, may be counterproductive because less stringent measures to limit future antigen exposure are undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOME OF HP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of persons with HP experience near total recovery of lung function, which in some cases may take several years after the inciting exposure ceases. Bird fancier's HP appears to have a worse prognosis than farmer's lung. The prognoses of other varieties of HP are less well described. In general, patients with evidence of pulmonary fibrosis on surgical lung biopsy have a poorer prognosis than those without such changes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Farmer's lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many investigators have studied the clinical course of farmer's lung and have reached a similar conclusion: most farmers recover from their original illness with only minor, if any, functional abnormalities, and very few progress to an advanced, debilitated state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/4,5,15,19,20\">",
"     4,5,15,19,20",
"    </a>",
"    ]. Approximately 50 percent of farmers develop chronic lung impairment, but the alterations are usually minor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/19\">",
"     19",
"    </a>",
"    ]. Most have obstructive abnormalities, often associated with emphysematous changes on high resolution CT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. As an example, one 14 year study of 89 patients with farmer's lung and 84 controls matched for age, sex, and smoking habits found a higher incidence of airflow obstruction in those with farmer's lung (33 versus 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, PaO",
"    <sub>",
"     2",
"    </sub>",
"    improves more rapidly than the FVC, while recovery of the DLCO takes longest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/20\">",
"     20",
"    </a>",
"    ]. The pulmonary function of farmer's lung patients continues to improve for up to two years after the initial acute episode, and this improvement may be seen even if exposure continues.",
"   </p>",
"   <p>",
"    Attempts to identify factors which influence prognosis have yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/1,9,15,23-25\">",
"     1,9,15,23-25",
"    </a>",
"    ]. However, repeated mild attacks appear more likely to result in disability than a single, acute attack [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. This may reflect better adherence to antigen avoidance measures in the latter group, as well as resolution of granulomatous inflammation before significant pulmonary fibrosis has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bird fancier's lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bird fancier's lung (also called pigeon breeder's disease) has not been as well studied as farmer's lung, but its prognosis appears worse. We and others have noted that many of our chronic, progressive, and fatal cases of HP had disease secondary to bird antigen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Nevertheless, some patients do relatively well despite continued antigen exposure after an acute episode of HP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/32\">",
"     32",
"    </a>",
"    ]. In one report of 18 such patients who were followed for 10 years, only five had troublesome symptoms and four had some residual abnormalities in pulmonary function.",
"   </p>",
"   <p>",
"    The poorer outcome in some patients with this disorder may be due to a higher degree of exposure to HP antigens than in farmer's lung and to the persistence of avian antigens in the home environment despite attempts at decontamination. Continued domestic exposure may account for the substantial mortality (29 percent at five years) seen in Mexican patients with chronic pigeon breeder's lung [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of factors affect prognosis with bird fancier's lung [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/17,33-37\">",
"     17,33-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration of exposure appears important. One study of nine patients found complete recovery among persons exposed to bird antigens for less than six months but documented residual abnormalities in those with longer exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/33\">",
"       33",
"      </a>",
"      ]. Similar findings were reported in a series of 24 patients with bird fancier's lung in which patients exposed for less than two years had a more favorable outcome than those exposed for a longer period [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A wide range of histopathologic changes has been reported among patients with bird fancier's lung, and these findings may help predict the subsequent clinical course of disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition to hypersensitivity pneumonitis, changes associated with several forms of idiopathic interstitial pneumonia have been identified. As an example, patients with organizing pneumonia or cellular nonspecific interstitial pneumonia (NSIP) appear to have a better prognosis than those with evidence of fibrosing pneumonitis (either fibrotic NSIP or a UIP-like pattern with a distinct centrilobular fibrosis) on biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/17,38\">",
"       17,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"       \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presentation (acute, subacute, or chronic) may correlate with recovery or progression. In a study of 18 patients followed for a median of 11 years, an acute presentation was associated with a better prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/37\">",
"       37",
"      </a>",
"      ]. This association has been noted in some [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/39\">",
"       39",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/33\">",
"       33",
"      </a>",
"      ] subsequent studies.",
"     </li>",
"     <li>",
"      The presence of digital clubbing predicts a worse outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Older patients tend to have a less complete recovery than younger patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Greater exposure intensity results in accelerated declines in lung function [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neither the degree or type of lung function abnormality nor chest radiographs at the time of diagnosis correlate with outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/33,37\">",
"       33,37",
"      </a>",
"      ]. However, high resolution computed tomography (HRCT) patterns may be useful in predicting prognosis of chronic HP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. In particular, a greater severity of traction bronchiectasis and increased extent of honeycombing are associated with increasing mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7719/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Environmental controls to reduce or eliminate exposure to the agricultural dusts, bioaerosols, and chemicals that cause hypersensitivity pneumonitis (HP) remain the cornerstone of prevention and treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of HP can be reduced by diminishing exposure to provocative antigens. This may be accomplished by minimizing contact with potential inciting agents, reducing microbial contamination of the work or home environment, or using protective equipment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with HP should be strongly encouraged to completely avoid (preferred) or minimize ongoing exposure. In patients with mild or moderate disease, avoidance may be adequate to resolve the clinical manifestations of the disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Antigen avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid treatment with 0.5 to 1 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per kilogram of ideal body weight per day (up to 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should be considered for severely symptomatic patients, especially if there is physiologic and radiographic evidence of progression of disease. The initial dose is maintained for one to two weeks and is then tapered over the next two to four weeks. Maintenance therapy is rarely required. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with HP experience near total recovery of lung function, which in some cases may take several years after the inciting exposure ceases. Patients with pulmonary fibrosis on surgical lung biopsy have a poorer prognosis than those without such changes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Outcome of HP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many farmers with HP are able to continue living and working on their farms after resolution of the initial episode. Long term studies have found mild obstructive airways disease in many farmers after initial HP, although the factors that lead to mild airways disease versus progressive HP are not known. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Farmer's lung'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bird fancier's lung appears to have a worse prognosis than farmer's lung; this may be due to a higher degree of exposure to and persistence of avian antigens in the home environment compared with exposures to antigens that cause farmer's lung. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bird fancier's lung'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/1\">",
"      Reynolds HY. Hypersensitivity pneumonitis: correlation of cellular and immunologic changes with clinical phases of disease. Lung 1988; 166:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/2\">",
"      Girard M, Isra&euml;l-Assayag E, Cormier Y. Pathogenesis of hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol 2004; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/3\">",
"      Rose CS. Water-related lung diseases. Occup Med 1992; 7:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/4\">",
"      Cormier Y, B&eacute;langer J. Long-term physiologic outcome after acute farmer's lung. Chest 1985; 87:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/5\">",
"      Braun SR, doPico GA, Tsiatis A, et al. Farmer's lung disease: long-term clinical and physiologic outcome. Am Rev Respir Dis 1979; 119:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/6\">",
"      Jacobs RL, Andrews CP, Jacobs FO. Hypersensitivity pneumonitis treated with an electrostatic dust filter. Ann Intern Med 1989; 110:115.",
"     </a>",
"    </li>",
"    <li>",
"     Rose C. Hypersensitivity pneumonitis and other disorders caused by organic agents. In: Pulmonary Respiratory Therapy Secrets, Parsons PE, Heffner JE (Eds), Hanley &amp; Belfus, Philadelphia 1997. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/8\">",
"      Cuthbert OD, Gordon MF. Ten year follow up of farmers with farmer's lung. Br J Ind Med 1983; 40:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/9\">",
"      Barbee RA, Callies Q, Dickie HA, Rankin J. The long-term prognosis in farmer's lung. Am Rev Respir Dis 1968; 97:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/10\">",
"      Craig TJ, Hershey J, Engler RJ, et al. Bird antigen persistence in the home environment after removal of the bird. Ann Allergy 1992; 69:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/11\">",
"      M&ouml;nk&auml;re S. Influence of corticosteroid treatment on the course of farmer's lung. Eur J Respir Dis 1983; 64:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/12\">",
"      Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 1992; 145:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/13\">",
"      Patel AM, Ryu JH, Reed CE. Hypersensitivity pneumonitis: current concepts and future questions. J Allergy Clin Immunol 2001; 108:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/14\">",
"      Carlsen KH, Leegaard J, Lund OD, Skjaervik H. Allergic alveolitis in a 12-year-old boy: treatment with budesonide nebulizing solution. Pediatr Pulmonol 1992; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/15\">",
"      M&ouml;nk&auml;re S, Haahtela T. Farmer's lung--a 5-year follow-up of eighty-six patients. Clin Allergy 1987; 17:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/16\">",
"      Vourlekis JS, Schwarz MI, Cherniack RM, et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 2004; 116:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/17\">",
"      Ohtani Y, Saiki S, Kitaichi M, et al. Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 2005; 60:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/18\">",
"      Sahin H, Brown KK, Curran-Everett D, et al. Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival. Radiology 2007; 244:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/19\">",
"      Lalancette M, Carrier G, Laviolette M, et al. Farmer's lung. Long-term outcome and lack of predictive value of bronchoalveolar lavage fibrosing factors. Am Rev Respir Dis 1993; 148:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/20\">",
"      Kokkarinen JI, Tukiainen HO, Terho EO. Recovery of pulmonary function in farmer's lung. A five-year follow-up study. Am Rev Respir Dis 1993; 147:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/21\">",
"      Erkinjuntti-Pekkanen R, Kokkarinen JI, Tukiainen HO, et al. Long-term outcome of pulmonary function in farmer's lung: a 14 year follow-up with matched controls. Eur Respir J 1997; 10:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/22\">",
"      Erkinjuntti-Pekkanen R, Rytkonen H, Kokkarinen JI, et al. Long-term risk of emphysema in patients with farmer's lung and matched control farmers. Am J Respir Crit Care Med 1998; 158:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/23\">",
"      Phanuphak P, Salvaggio J, Fink J, Kohler P. Incidence of serum precipitins against organic-dust antigens in different populations by counterimmunoelectrophoresis. Chest 1975; 68:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/24\">",
"      Hapke EJ, Seal RM, Thomas GO, et al. Farmer's lung. A clinical, radiographic, functional, and serological correlation of acute and chronic stages. Thorax 1968; 23:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/25\">",
"      Laviolette M, Cormier Y, Loiseau A, et al. Bronchoalveolar mast cells in normal farmers and subjects with farmer's lung. Diagnostic, prognostic, and physiologic significance. Am Rev Respir Dis 1991; 144:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/26\">",
"      Leblanc P, B&eacute;langer J, Laviolette M, Cormier Y. Relationship among antigen contact, alveolitis, and clinical status in farmer's lung disease. Arch Intern Med 1986; 146:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/27\">",
"      Grammer LC, Roberts M, Lerner C, Patterson R. Clinical and serologic follow-up of four children and five adults with bird-fancier's lung. J Allergy Clin Immunol 1990; 85:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/28\">",
"      Remy-Jardin M, Remy J, Wallaert B, M&uuml;ller NL. Subacute and chronic bird breeder hypersensitivity pneumonitis: sequential evaluation with CT and correlation with lung function tests and bronchoalveolar lavage. Radiology 1993; 189:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/29\">",
"      P&eacute;rez-Padilla R, Salas J, Chapela R, et al. Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia. Am Rev Respir Dis 1993; 148:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/30\">",
"      Buschman DL, Gamsu G, Waldron JA Jr, et al. Chronic hypersensitivity pneumonitis: use of CT in diagnosis. AJR Am J Roentgenol 1992; 159:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/31\">",
"      Fink JN, Sosman AJ, Barboriak JJ, et al. Pigeon breeders' disease. A clinical study of a hypersensitivity pneumonitis. Ann Intern Med 1968; 68:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/32\">",
"      Bourke SJ, Banham SW, Carter R, et al. Longitudinal course of extrinsic allergic alveolitis in pigeon breeders. Thorax 1989; 44:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/33\">",
"      Allen DH, Williams GV, Woolcock AJ. Bird breeder's hypersensitivity pneumonitis: progress studies of lung function after cessation of exposure to the provoking antigen. Am Rev Respir Dis 1976; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/34\">",
"      de Gracia J, Morell F, Bofill JM, et al. Time of exposure as a prognostic factor in avian hypersensitivity pneumonitis. Respir Med 1989; 83:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/35\">",
"      Schmidt CD, Jensen RL, Christensen LT, et al. Longitudinal pulmonary function changes in pigeon breeders. Chest 1988; 93:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/36\">",
"      Sansores R, Salas J, Chapela R, et al. Clubbing in hypersensitivity pneumonitis. Its prevalence and possible prognostic role. Arch Intern Med 1990; 150:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/37\">",
"      Zacharisen MC, Schlueter DP, Kurup VP, Fink JN. The long-term outcome in acute, subacute, and chronic forms of pigeon breeder's disease hypersensitivity pneumonitis. Ann Allergy Asthma Immunol 2002; 88:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/38\">",
"      Miyazaki Y, Tateishi T, Akashi T, et al. Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 2008; 134:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/39\">",
"      Ohtani Y, Saiki S, Sumi Y, et al. Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol 2003; 90:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/40\">",
"      Tateishi T, Ohtani Y, Takemura T, et al. Serial high-resolution computed tomography findings of acute and chronic hypersensitivity pneumonitis induced by avian antigen. J Comput Assist Tomogr 2011; 35:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7719/abstract/41\">",
"      Walsh SL, Sverzellati N, Devaraj A, et al. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol 2012; 22:1672.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4311 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-CCD80C94BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7719=[""].join("\n");
var outline_f7_34_7719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Reduction of antigenic burden",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Design of facilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Protective devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antigen avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOME OF HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Farmer's lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bird fancier's lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=related_link\">",
"      Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_34_7720="Clinical trials of HIV antiretroviral therapy: Integrase inhibitors";
var content_f7_34_7720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7720/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7720/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7720/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7720/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/34/7720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 integrase is essential for viral replication; integrase inserts viral DNA into the cellular genome through two catalytic reactions. Loss of integrase activity disrupts the viral life cycle. Inhibitors of the integrase function have potent in vitro and in vivo antiviral activity.",
"   </p>",
"   <p>",
"    This topic will discuss the two integrase inhibitors available for clinical use:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , the first agent available in this class [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/1\">",
"     1",
"    </a>",
"    ], and elvitegravir, which is available in a coformulated tablet in combination with cobicistat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    . The other integrase inhibitor (dolutegravir) that is currently in development is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31956?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Agents in advanced stages of development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for initiating antiretroviral therapy (ART) in the chronically infected HIV-infected patient, relative efficacy of different regimens, patient evaluation, and laboratory monitoring are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RALTEGRAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    (MK-0518) is an integrase inhibitor with potent in vitro activity against both wild-type and multidrug-resistant HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/2\">",
"     2",
"    </a>",
"    ]. It is metabolized by hepatic glucuronidation and has no effect on cytochrome 3A4 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/3\">",
"     3",
"    </a>",
"    ]. The dose of raltegravir is 400 mg twice daily. Dosing adjustments are not necessary in patients with renal or mild to moderate hepatic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    has demonstrated significant efficacy in treatment-naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This can be illustrated by the results from the two largest trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, double-blind, randomized controlled trial was designed to evaluate the safety and efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      in 198 treatment-naive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/6\">",
"       6",
"      </a>",
"      ]. This dose-ranging study evaluated raltegravir at doses of 100, 200, 400, and 600 mg twice daily versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , all in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      . The mean HIV RNA level ranged from 4.6 to 4.8 log(10)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      at baseline; 34 percent had a viral load &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"      The mean CD4 count in the various treatment arms ranged from 271 to 338",
"      <span class=\"nowrap\">",
"       cells/microL.",
"       <br/>",
"       <br/>",
"       At",
"      </span>",
"      weeks two, four, and eight, the proportion of patients achieving an HIV RNA level &lt;50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      was greater in each of the raltegravir dosing groups than in the efavirenz group. These differences diminished over time and, at 24 and 48 weeks of follow-up, patients in all arms had similar rates of viral suppression. The average increase in CD4+ T-cells was also similar.",
"      <br/>",
"      <br/>",
"      Treatment was well tolerated across all doses of raltegravir. At weeks 24 and 48, lipid profiles remained unchanged in the raltegravir groups, but were elevated in the efavirenz group. Two patients with virologic failure in the raltegravir arm harbored the N155H mutation, characteristic of raltegravir resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"       \"Primer on interpretation of HIV drug resistance testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a subsequent double-blind non-inferiority trial, 563 treatment-naive patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      (400 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (600 mg daily), both in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients were stratified by baseline viral load; 53 percent had a viral load &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"      Approximately one-half of the patients had a CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      The primary endpoint at week 48 was achievement of viral suppression (ie, &lt;50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      of HIV RNA). In the statistical analysis, all patients who did not complete the study were considered virologic failures.",
"      <br/>",
"      <br/>",
"      In the main analysis, 86 percent of the raltegravir group achieved the primary endpoint compared with 82 percent of the efavirenz group, indicating noninferiority of raltegravir to efavirenz. The time to achieve viral suppression was significantly shorter in the raltegravir arm, although the clinical significance of this observation is unclear. The mean increase in CD4 cells was also significantly greater in the raltegravir arm (189 versus 163",
"      <span class=\"nowrap\">",
"       cells/mm3).",
"      </span>",
"      Furthermore, 96-week follow-up suggested ongoing durability of raltegravir with comparable rates of viral suppression compared with efavirenz (ie, 81 versus 79 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serious adverse events occurred with similar frequency (&lt;2 percent) in both treatment groups.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    was associated with significantly better lipid profiles (lower LDL, total cholesterol and triglyceride levels) than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    These results suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    has rapid, potent, and durable efficacy with a lower rate of adverse events. This study supports the use of raltegravir with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    for treatment-naive patients.",
"   </p>",
"   <p>",
"    Although there was interest in once-daily dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , a clinical trial demonstrated that greater proportions of patients achieved viral suppression on twice-daily dosing compared with once-daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, all patients should be treated with a twice-daily schedule of raltegravir when used as part of combination antiretroviral therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    has also demonstrated significant efficacy in treatment-experienced patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dose-ranging trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter, double-blind dose-ranging study randomly assigned 179 patients with documented genotypic and phenotypic resistance to each of the three classes of ART to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    (200 mg, 400 mg, or 600 mg twice daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/10\">",
"     10",
"    </a>",
"    ]. All patients were also given optimized background therapy; however, none received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    . The study population was heavily treatment-experienced; the median number of previous antiretroviral medications was 12. Of the 166 patients in whom HIV co-receptor tropism was determined at baseline, 68 (41 percent) had dual or mixed tropic viruses. This observation is consistent with the high proportion of dual-mixed tropic virus that is seen in treatment-experienced patients with longstanding HIV.",
"   </p>",
"   <p>",
"    The primary endpoints were change in viral load from baseline at week 24 and safety. The study was significant for the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An approximate 2 log decline in HIV RNA was seen in all",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      groups as early as two weeks after initiation; this effect was sustained throughout the 24-week period of the study.",
"     </li>",
"     <li>",
"      Immunologic benefit was seen in all the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      arms, although the magnitude of the CD4 cell count was smaller in the 200 mg dosing group.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      had a safety profile comparable to placebo at all doses.",
"     </li>",
"     <li>",
"      Viral suppression was demonstrated to be durable at 48 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/11\">",
"       11",
"      </a>",
"      ]. Thirty-four of 35 patients who had virologic failure had evidence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      mutations at either Q148 or N155. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"       \"Primer on interpretation of HIV drug resistance testing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects have included nausea, headache, diarrhea and pyrexia. Creatine kinase elevations and myopathy have been reported, although the relationship to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    is unclear. As noted above, the drug is metabolized primarily by glucuronidation and is not a known CDP450 inducer, inhibitor, or substrate. As seen in other studies, hepatotoxicity was more common in patients with underlying chronic viral hepatitis. No dose reductions are recommended at this time in patients with hepatic or renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     BENCHMRK trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two identical double-blind phase III trials are being conducted in different geographic regions to evaluate the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    (400 mg twice daily), as compared with placebo, both in combination with optimized background therapy (OBT) in patients with three-class HIV drug resistance (BENCHMRK trials 1 and 2). OBT was allowed to include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    , which was not licensed at the time of the trial. The planned total duration of each study is at least 156 weeks; 48-week interim data show the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppression of HIV RNA below 50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      was achieved in a significantly higher proportion of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      arm compared to the placebo arm (62 versus 33 percent, respectively). Virologic response rates were 51, 61, and 71 percent when raltegravir was given in combination with zero, one, or two other active drugs, respectively.",
"     </li>",
"     <li>",
"      The mean change in CD4 cell count between baseline and week 48 was also significantly higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      arm compared with the placebo arm (109 versus 45",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      Genotyping was performed in 94",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      recipients with virologic failure; integrase mutations associated with phenotypic resistance arose during treatment in 64 patients (68 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/13\">",
"       13",
"      </a>",
"      ]. The prevalence of resistance mutations was lower among isolates from patients who were given two or more active drugs in addition to raltegravir, as compared with none (33 versus 78 percent).",
"     </li>",
"     <li>",
"      The overall adverse event rates between the groups were similar. However, 16 of 462",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      recipients (3.5 percent) and 4 of 237 placebo recipients (1.7 percent) were diagnosed with new, recurrent, or progressive cancer during the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the disproportionate number of cancer diagnoses, a subsequent combined analysis of four trials determined that the relative risk of cancer associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , as compared to placebo, was 1.2 (95% CI, 0.4-4.1). Although no evidence of carcinogenicity was apparent from the preclinical data on raltegravir, continued safety monitoring is ongoing; 96-week data from the combined trials found rates of cancer that were comparable between both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     SWITCHMRK trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    has been associated with favorable lipid effects in HIV-infected patients. Two parallel multicenter, double-blind, randomized studies were performed in 707 patients with documented viral suppression on combination antiretroviral therapy (ART) containing",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    <span class=\"nowrap\">",
"     (LPV/r)",
"    </span>",
"    to evaluate the effect of switching from",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    to raltegravir versus continuation of the same ART [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/15\">",
"     15",
"    </a>",
"    ]. Primary endpoints included the mean percentage change in lipids at week 12 and demonstration of non-inferiority with respect to virologic efficacy.",
"   </p>",
"   <p>",
"    At week 12, the lipid profile (both cholesterol and triglycerides) was significantly improved in patients who were switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    . However, the trial was terminated at the interim analysis because there were significantly more virologic failures in those who switched than in those who did not (16 versus 9 percent).",
"   </p>",
"   <p>",
"    A post-hoc analysis found that the virologic response rates were similar in patients who were on their first HIV treatment regimen while those with a history of virologic failure had breakthrough viremia with documented",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    resistance mutations. These data are consistent with previous published data suggesting that raltegravir is most efficacious when combined with two or more active agents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/13,16\">",
"     13,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Switch from enfuvirtide to raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open label trial (EASIER), 170 patients with multidrug-resistant HIV who were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    -based regimens were randomly assigned to continue enfuvirtide or switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients in both treatment groups had similar virologic failure rates of 1 percent each over the 24-week study period. No significant changes in CD4 cell counts occurred in either arm. A switch to raltegravir offers the advantage of an oral regimen for long-term ART administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27660883\">",
"    <span class=\"h2\">",
"     Switching from a protease inhibitor to raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In light of the encouraging results from the EASIER trial, another trial was designed to evaluate the efficacy of switching 222 virologically suppressed patients from a protease inhibitor (PI)-containing regimen to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -containing regimen. Patients were randomly assigned to either twice-daily dosing of raltegravir (400 mg BID) or an experimental arm using once-daily dosing (800 mg) versus continuation of the PI-containing regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/18\">",
"     18",
"    </a>",
"    ]. Preliminary data suggest that the efficacy of raltegravir was comparable between the dosing arms. However, this study confirmed similar observations from the SWITCHMRK trial; virologic failure was significantly higher among those patients with prior NRTI resistance (16 versus 0.7 percent).",
"   </p>",
"   <p>",
"    Another open-label trial (SPIRAL) of 273 patients with viral suppression on PI-containing regimens demonstrated that the patients who switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    had similar rates of virologic suppression as those who continued their PI-based ART (97 versus 95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/19\">",
"     19",
"    </a>",
"    ]. As seen in the SWITCHMRK, raltegravir use was also associated with an improved lipid profile at 48 weeks of follow-up. Of note, the median duration of viral suppression prior to entrance in the SPIRAL study was six years, which may have accounted for the low rates of virologic failure seen in this study, despite the history of NRTI resistance in a subset of patients.",
"   </p>",
"   <p>",
"    A third study evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    once or twice daily as a substitution for a boosted PI in patients receiving two NRTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/20\">",
"     20",
"    </a>",
"    ]. While the study was not powered to evaluate the efficacy of once- or twice-daily raltegravir dosing, it confirmed that substitution of raltegravir for a boosted PI in patients with significant NRTI resistance was associated with a higher risk of virologic failure.",
"   </p>",
"   <p>",
"    In aggregate, these studies support the concept that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    may be substituted safely for another active drug, provided that there is a fully active background regimen. In the case of possible substitution for boosted PIs, this should only be done if there is no concomitant NRTI resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    was approved for treatment-experienced patients in October 2007 at a dose of 400 mg twice daily with or without food. This approval was based on results of two identical Phase III studies (BENCHMRK I and II), which compared raltegravir to matching placebo, both with an optimized background regimen. A statistically significant greater virologic suppression rate was seen in the raltegravir arm, with no adverse events occurring more frequently than placebo.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    should not be used in a &ldquo;switch strategy&rdquo;&nbsp;unless the other agents in the regimen are fully active.&nbsp;Data demonstrate that raltegravir can be safely substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    . However, raltegravir may not always work as a substitution for PIs, which have a higher barrier to resistance. Raltegravir resistance is associated with emergence of mutations at either Q148R or N155H. The risk of resistance&nbsp;is lower&nbsp;when coadministered with other active agents.",
"   </p>",
"   <p>",
"    To report suspected adverse reactions, contact Merck and Co, Inc. at 877-888-4231 or the FDA at 1-800-FDA-1088 or",
"    <a class=\"external\" href=\"file://www.fda.gov/medwatch\">",
"     www.fda.gov/medwatch",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Raltegravir intensification strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although potent ART suppresses HIV RNA to nondetectable levels in blood plasma, immune activation markers remain elevated compared with HIV-uninfected controls. Low-level replication in the latent viral reservoir may be responsible for T cell activation in the absence of detectable viremia with standard viral detection assays. Studies of the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    for treatment intensification have shown conflicting results, although the majority of studies do not show any benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/14,21-23\">",
"     14,21-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized placebo-controlled trial was conducted in 30 patients with suboptimal CD4 responses despite attainment of viral suppression, to evaluate whether the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      for 24 weeks would lead to an improvement in immune recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/24\">",
"       24",
"      </a>",
"      ]. As compared with placebo, raltegravir did not have a significant effect on T cell activation markers or the size of the latent viral reservoir, as measured by proviral DNA assays.",
"     </li>",
"     <li>",
"      In a study of 10 patients with long-term viral suppression on ART, median plasma HIV RNA levels as detected by a single copy assay (limit of detection 0.2",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      of plasma) were unchanged after four weeks of intensification therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, 45 patients with viral suppression intensified their ART regimen with the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      ; another 24 patients continued their stable ART combination regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/21\">",
"       21",
"      </a>",
"      ]. At 24 weeks, patients assigned to raltegravir intensification had significantly lower CD8 T cell activation markers, which appeared to be linked to a decline in residual viral replication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these results, there is no indication for the strategy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    intensification in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1981991\">",
"    <span class=\"h1\">",
"     ELVITEGRAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In August 2012, the US Food and Drug Administration (FDA) approved the use of a single tablet coformulation (ie, Stribild, also known as &ldquo;Quad&rdquo;), which combines elvitegravir, cobicistat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    for use in treatment-na&iuml;ve HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4926570\">",
"    <span class=\"h2\">",
"     Treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase 3 trial comparing elvitegravir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and cobicistat with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , tenofovir, and emtricitabine among 708 HIV-infected patients demonstrated the following results at 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral suppression rates (ie, HIV RNA &lt;50",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      were noninferior among patients taking elvitegravir-containing ART compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      -containing ART (ie, 90 versus 87 percent).",
"     </li>",
"     <li>",
"      Viral suppression rates were also noninferior among the subset of patients with a baseline viral load &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (ie, 85 versus 82 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, elvitegravir was well tolerated with a favorable metabolic profile.",
"   </p>",
"   <p>",
"    In a separate phase 3 trial of 700 patients, elvitegravir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and cobicistat was also found to be noninferior to the combination regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , emtricitabine, plus tenofovir dosed over 48 weeks (viral suppression in 88 versus 84 percent), including among those patients with a baseline viral load of &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (ie, 84 and 82 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/26\">",
"     26",
"    </a>",
"    ]. CD4 cell count increases were significantly higher in the elvitegravir arm compared with the efavirenz arm (ie, 239 versus 206).",
"   </p>",
"   <p>",
"    Nausea was more common among patients in the elvitegravir arm, while central nervous system adverse events and rash were more common among patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    arm. Increases in total cholesterol and LDL were significantly lower in the elvitegravir-containing arm. More patients in the elvitegravir arm discontinued study drug for renal adverse effects (five versus none).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4926535\">",
"    <span class=\"h2\">",
"     Treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not yet available as a stand-alone drug, elvitegravir appears to be effective as part of an optimized regimen for treatment-experienced patients. In a noninferiority phase 3 trial conducted in 13 countries, the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted elvitegravir was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    among 702 patients with a history of virologic failure; patients also received an open-label background regimen of a fully active, ritonavir-boosted protease inhibitor and a second agent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7720/abstract/27\">",
"     27",
"    </a>",
"    ]. Two-thirds of the patients had documented HIV resistance to two or more ART drug classes and nearly half of the patients had a CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    The dosing of elvitegravir was based on the coadministered HIV protease inhibitor because of drug interactions. The trial demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral suppression of HIV RNA was achieved in similar proportions of patients taking elvitegravir compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      -containing ART in both the intention-to-treat analysis (ie, 59 versus 58 percent) and the per-protocol analysis (61 percent in both arms).",
"     </li>",
"     <li>",
"      The efficacy of elvitegravir was comparable to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      among patients with a baseline viral load &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Rates of serious adverse events were low in both arms (1 versus 2 percent). More patients assigned elvitegravir experienced diarrhea, while liver function test abnormalities were more common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantage of once-daily dosing of elvitegravir compared with twice-daily dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    could not be assessed since patients assigned to elvitegravir received a placebo dose to mask treatment assignment.",
"   </p>",
"   <p>",
"    Of note, elvitegravir has a similar resistance profile to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    so is not expected to be useful in patients who have raltegravir resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31890611\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials of both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    and elvitegravir in treatment-naive patients, approximately half of those with virologic failure developed resistance to both the integrase inhibitor and at least one of the nucleoside reverse transcriptase inhibitors (NRTIs). Though the specific integrase inhibitor mutations selected may be different after raltegravir or elvitegravir exposure, there is cross-resistance between the two; hence, switching from one to the other would not be expected to have a significant antiviral effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV-1 integrase is essential for viral replication; inhibitors of the integrase function demonstrate potent antiviral activity.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      was the first integrase inhibitor to be available for clinical use in treatment-naive and treatment-experienced patients; elvitegravir was approved in 2012 for use in treatment-naive patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6898163\">",
"    <span class=\"h2\">",
"     Raltegravir",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized controlled trial comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      in treatment-naive patients, raltegravir led to comparable rates of viral suppression and immunologic benefit at 24 and 48 weeks; raltegravir was also associated with higher rates of early virologic suppression than efavirenz at weeks two, four, and eight. The role of raltegravir in this patient population is still under study. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment-naive patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In heavily treatment-experienced patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      plus optimized background therapy led to an approximate 2-log decline in HIV RNA as early as two weeks after the initiation of therapy, which was sustained at 24 weeks. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In comparative clinical trials in treatment-experienced patients, the overall adverse event profile of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      is similar to placebo. Adverse effects seen rarely with raltegravir include myositis and rash. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the patients who had virologic failure had evidence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      mutations at either Q148 or N155. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients receiving two nucleoside reverse transcriptase inhibitors (NRTIs) with a boosted protease inhibitor (PI),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      substitution for the boosted PI improves lipids, but is associated with a higher risk of virologic failure if there is a history of NRTI resistance. (See",
"      <a class=\"local\" href=\"#H27660883\">",
"       'Switching from a protease inhibitor to raltegravir'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6898184\">",
"    <span class=\"h2\">",
"     Elvitegravir",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In August 2012, the US Food and Drug Administration (FDA) approved the use of a single tablet coformulation (ie, Stribild; also known as &ldquo;Quad&rdquo;), which combines elvitegravir, cobicistat,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      , for use in treatment-na&iuml;ve HIV-infected patients. This approval was based on two phase 3 trials that demonstrated noninferiority of an elvitegravir-containing ART regimen compared to an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      -based regimen or an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      -based regimen. Noninferiority was also demonstrated in the patient subgroup with high levels of HIV RNA (&gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1981991\">",
"       'Elvitegravir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In regimens that also included a boosted protease inhibitor (PI,) once-daily elvitegravir was noninferior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      in treatment-experienced patients. Elvitegravir is not currently available as a stand-alone drug, but approval is expected in the future. (See",
"      <a class=\"local\" href=\"#H1981991\">",
"       'Elvitegravir'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/1\">",
"      Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/2\">",
"      Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/3\">",
"      Wong JK, Lampiris H. Covering all the bases: targeting HIV-1 integrase. J Acquir Immune Defic Syndr 2006; 43:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/4\">",
"      Two new drugs for HIV infection. Med Lett Drugs Ther 2008; 50:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/5\">",
"      Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/6\">",
"      Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/7\">",
"      Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796.",
"     </a>",
"    </li>",
"    <li>",
"     Lennox J, DeJesus E, Lazzarin A, et al. Raltegravir Demonstrates Durable Efficacy through 96 Weeks (Wk): Results from STARTMRK, A Phase III Study of Raltegravir (RAL)-based vs Efavirenz (EFV)-based Therapy in Treatment-Naive HIV+ Patients (Pts). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009). San Francisco. September 12-15, 2009. Abstract H-924b.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/9\">",
"      Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/10\">",
"      Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261.",
"     </a>",
"    </li>",
"    <li>",
"     Grinsztejn B. 48 week efficacy and safety of MK-0158, a novel HIV-1 integrase inhibitor in patients with triple class resistant virus. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2007 [Abstract #H713].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/12\">",
"      Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/13\">",
"      Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/14\">",
"      Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/15\">",
"      Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/16\">",
"      Kilby JM. Switching HIV therapies: competing host and viral factors. Lancet 2010; 375:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/17\">",
"      De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009; 49:1259.",
"     </a>",
"    </li>",
"    <li>",
"     Vispo E, et al. Simplication from protease inhibitors to once or twice daily raltegreavir: the ODIS trial. Program and abstracts of the International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract MOAB0102.",
"    </li>",
"    <li>",
"     Martinez E, Larrousse M, Llibre JM, et al. Simplification of antiretroviral therapy by switching from ritonavir-boosted protease inhibitors to raltegravir in virologically suppressed HIV-1-infected patients (SPIRAL): a randomised open-label trial. XVIII International AIDS Conference. July 18-23, 2010. Vienna. Abstract MOAB0103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/20\">",
"      Vispo E, Barreiro P, Maida I, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010; 11:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/21\">",
"      Buz&oacute;n MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/22\">",
"      McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/23\">",
"      Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960.",
"     </a>",
"    </li>",
"    <li>",
"     Hatano H, et al. Raltegravir intensification in antiretroviral-treated patients exhibiting a suboptimal CD4+ T cell response. Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco, CA, Abst# 101LB.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/25\">",
"      DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/26\">",
"      Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7720/abstract/27\">",
"      Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3788 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7720=[""].join("\n");
var outline_f7_34_7720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RALTEGRAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dose-ranging trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - BENCHMRK trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SWITCHMRK trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Switch from enfuvirtide to raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27660883\">",
"      Switching from a protease inhibitor to raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Raltegravir intensification strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1981991\">",
"      ELVITEGRAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4926570\">",
"      Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4926535\">",
"      Treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31890611\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6898163\">",
"      Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6898184\">",
"      Elvitegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31956?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Agents in advanced stages of development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_34_7721="Chronic hepatitis C - high power Gomori trichrome";
var content_f7_34_7721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Chronic hepatitis C (high power, Gomori trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is minimal scarring and mononuclear cell inflammation in an enlarged portal triad. The limiting plate, the rim of hepatocytes that separates the parenchyma from the portal triad, is almost intact. A few hepatocytes are trapped by fingers of scar tissue that cross the limiting plate and are necrotic (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7721=[""].join("\n");
var outline_f7_34_7721=null;
var title_f7_34_7722="Overview of nontuberculous mycobacterial skin and soft tissue infections in children";
var content_f7_34_7722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of nontuberculous mycobacterial skin and soft tissue infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7722/contributors\">",
"     Andrea T Cruz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7722/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/34/7722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/34/7722/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/34/7722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1060356409\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/1\">",
"     1",
"    </a>",
"    ]. They have been isolated from numerous environmental sources including water, soil, food products, and domestic and wild animals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"     2",
"    </a>",
"    ]. Nosocomial transmission has occurred with medical equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 130 species of have been identified, not all of which have been documented to cause disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. NTM pathogens are classified as rapidly growing or slowly-growing (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ). Rapidly growing species grow within seven days and include",
"    <em>",
"     Mycobacterium fortuitum, M. abscessus,",
"    </em>",
"    and",
"    <em>",
"     M. chelonae",
"    </em>",
"    . Slowly growing species require several weeks to grow and include",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC),",
"    <em>",
"     M. marinum,",
"    </em>",
"    and",
"    <em>",
"     M. kansasii",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenopathy, skin and soft tissue infection (SSTI), pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in children with immune compromise).",
"   </p>",
"   <p>",
"    This topic will provide an overview of NTM SSTI infections, focussing on immune competent children. NTM lymphadenitis, pulmonary infections, disseminated infection and bacteremia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/282?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial pulmonary infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356416\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of nontuberculous mycobacterial (NTM) skin and soft tissue infections (SSTI) include",
"    <em>",
"     M. fortuitum, M. abscessus,",
"    </em>",
"    and",
"    <em>",
"     M. chelonae",
"    </em>",
"    , which are rapidly growing species; and",
"    <em>",
"     M. marinum,",
"    </em>",
"    and",
"    <em>",
"     M. ulcerans,",
"    </em>",
"    which are slowly growing species",
"    <em>",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/8,10-14\">",
"     8,10-14",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    Rapidly growing NTM species are resistant to commonly used disinfectants (eg, chlorine, formaldehyde, glutaraldehyde, organomercurial compounds), and may grow in nonspecific culture media [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology, culture requirements, and methods of speciation for NTM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356423\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the true burden of nontuberculous mycobacterial (NTM) infections in children are unavailable, in part because NTM infections may be asymptomatic and because NTM infections are not communicable, reporting of NTM infections is not required in the United States or many other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall prevalence of NTM disease appears to be increasing with time (possibly as a result of enhanced detection) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/14,15,17-20\">",
"     14,15,17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM are transmitted through environmental sources. Water (from both natural and treated sources) is a common reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. Aquatic transmission of NTM is facilitated by the formation of biofilms. Biofilms permit survival under a variety of environmental conditions. Detachment of biofilms allows dissemination of large numbers of organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin abrasions and penetrating trauma (including injections, piercing, acupuncture, tattooing) are the usual portal of entry for NTM skin and soft tissue infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/11,27-35\">",
"     11,27-35",
"    </a>",
"    ]. The incubation period is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/8\">",
"     8",
"    </a>",
"    ]. In outbreaks of cutaneous infection due to rapidly growing mycobacteria (eg,",
"    <em>",
"     M. abscessus",
"    </em>",
"    ,",
"    <em>",
"     M. chelonae",
"    </em>",
"    ,",
"    <em>",
"     M. fortuitum",
"    </em>",
"    ), the incubation period was approximately one month, but ranged from 12 to 119 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/29,36-38\">",
"     29,36-38",
"    </a>",
"    ]. In a review of 40 cases of",
"    <em>",
"     M. marinum",
"    </em>",
"    infection, the median incubation period was 21 days (range 5 to 270 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356430\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1510067549\">",
"    <span class=\"h2\">",
"     General features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacterial (NTM) skin and soft tissue infection (SSTI) typically occurs in healthy children with cutaneous exposure to NTM. NTM SSTI also occurs in children with immune deficiency and may be an early sign of disseminated NTM disease (",
"    <a class=\"graphic graphic_picture graphicRef86162 \" href=\"UTD.htm?35/46/36581\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,40-42\">",
"     2,40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link&amp;anchor=H564807774#H564807774\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM SSTI typically follow cutaneous trauma in swimming pools, aquariums, or natural bodies of water [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Cutaneous infection may occur at the site of surgery, vascular catheters, injections, piercing, or acupuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/11,27-33\">",
"     11,27-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous NTM infections are polymorphous [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Ulcerations (",
"    <a class=\"graphic graphic_picture graphicRef68569 \" href=\"UTD.htm?27/63/28658\">",
"     picture 2",
"    </a>",
"    ), plaques, folliculitis, erythematous papules, and nodules (",
"    <a class=\"graphic graphic_picture graphicRef81640 \" href=\"UTD.htm?5/19/5425\">",
"     picture 3",
"    </a>",
"    ) have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/46,48,49\">",
"     46,48,49",
"    </a>",
"    ]. The variations in clinical presentation may contribute to delays in diagnosis.",
"   </p>",
"   <p>",
"    NTM skin and soft tissue disease often starts as a slowly growing indurated area that begins to ulcerate after a few weeks. In contrast to other pyogenic infections, most NTM lesions are painless (",
"    <em>",
"     M. haemophilum",
"    </em>",
"    is the exception), systemic signs of inflammation are absent, and regional lymphadenopathy is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1510067648\">",
"    <span class=\"h2\">",
"     Rapidly growing NTM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous infections with rapidly growing mycobacteria (eg,",
"    <em>",
"     M. fortuitum, M. abscessus, M. chelonae)",
"    </em>",
"    may occur following puncture wounds, open fractures, or water exposure (eg, wading pools, whirlpool footbaths) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/15,36,38,50\">",
"     15,36,38,50",
"    </a>",
"    ]. In outbreaks of SSTI due to rapidly growing mycobacteria (eg,",
"    <em>",
"     M. abscessus",
"    </em>",
"    ,",
"    <em>",
"     M. chelonae",
"    </em>",
"    ,",
"    <em>",
"     M. fortuitum",
"    </em>",
"    ), the incubation period was approximately one month, but ranged from 12 to 119 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/29,36-38\">",
"     29,36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is a wide spectrum of manifestations, SSTI caused by a rapidly growing NTM usually manifest as localized cellulitis, draining abscess, or an individual nodule with minimal tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,40,51\">",
"     2,40,51",
"    </a>",
"    ]. These infections are clinically indistinguishable from those caused by other bacteria (eg,",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    ,",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231497626\">",
"    <span class=\"h2\">",
"     M. marinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSTI due to",
"    <em>",
"     M. marinum",
"    </em>",
"    usually follows cutaneous trauma in (or exposure of traumatized skin to) aquariums, swimming pools, or natural bodies of water [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The incubation period is variable; in a review of 40 cases of",
"    <em>",
"     M. marinum",
"    </em>",
"    SSTI, the median incubation period was 21 days (range 5 to 270 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     M. marinum",
"    </em>",
"    lesions are indolent and typically affect the elbows, knees, and dorsum of feet and hands [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Involvement of the regional lymph nodes is uncommon.",
"   </p>",
"   <p>",
"    There are two predominant presentations of",
"    <em>",
"     M. marinum",
"    </em>",
"    SSTI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/15,53\">",
"     15,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solitary papules that progress to shallow ulcers with scar formation; the lesions resolve over three to five weeks, with or without drainage.",
"     </li>",
"     <li>",
"      Nodules that spread cephalad from the site of inoculation (",
"      <a class=\"graphic graphic_picture graphicRef81640 \" href=\"UTD.htm?5/19/5425\">",
"       picture 3",
"      </a>",
"      ); this pattern is less common than solitary papules; it may resemble sporotrichosis and other forms of nodular lymphangitis; it generally resolves over several months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link&amp;anchor=H7#H7\">",
"       \"Soft tissue infections following water exposure\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=see_link&amp;anchor=H5#H5\">",
"       \"Lymphangitis\", section on 'Nodular lymphangitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231497680\">",
"    <span class=\"h2\">",
"     M. ulcerans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of",
"    <em>",
"     M. ulcerans",
"    </em>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39033?source=see_link&amp;anchor=H5#H5\">",
"     \"Buruli ulcer (Mycobacterium ulcerans infection)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231497649\">",
"    <span class=\"h2\">",
"     Immune-compromised host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions may be the earliest manifestation of disseminated disease in immune-compromised patients (",
"    <a class=\"graphic graphic_picture graphicRef86162 \" href=\"UTD.htm?35/46/36581\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,40-42,45\">",
"     2,40-42,45",
"    </a>",
"    ]. Immune-compromised patients may have multiple lesions and more frequent ulceration, abscess formation, or local metastatic disease than immune-competent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/50,55\">",
"     50,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link&amp;anchor=H564807774#H564807774\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231497657\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetration of NTM into deeper tissues can inoculate muscle planes or bone, resulting in chronic pyomyositis, tenosynovitis, and chronic osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/47\">",
"     47",
"    </a>",
"    ]. This occurs in approximately one-third of cases of",
"    <em>",
"     M. marinum",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Digital tenosynovitis caused by",
"    <em>",
"     M. marinum",
"    </em>",
"    is known as &ldquo;fish tank finger&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/56\">",
"     56",
"    </a>",
"    ]. The signs and symptoms are similar to those of tenosynovitis at other sites: pain and swelling over the tendon, a catching or snapping sensation with movement of the digit, and pain with passive extension of the finger. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20550?source=see_link&amp;anchor=H7#H7\">",
"     \"Infectious tenosynovitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of NTM osteomyelitis follow direct inoculation of the organism (eg, an open fracture); however, cases have occurred after blunt (non-penetrating) trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/57\">",
"     57",
"    </a>",
"    ]. The epidemiology, clinical features, and diagnosis of NTM osteomyelitis and treatment of NTM osteomyelitis in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39401?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/39/13946?source=see_link\">",
"     \"Treatment of osteomyelitis due to nontuberculous mycobacteria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356437\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic features of nontuberculous mycobacterial (NTM) skin and soft tissue infection (SSTI) include dermal granulomas (occasionally with suppuration), stellate abscesses, sinus tracts, and acute and chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/10,27,58,59\">",
"     10,27,58,59",
"    </a>",
"    ]. However, none of these features is pathognomonic. Eosinophilic infiltration is uncommon. Acid-fast bacilli are seen in a minority of cases (only 3 of 18 specimens in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominant histopathologic findings may vary depending upon the host&rsquo;s immune status. In a review of biopsy specimens from 27 patients with NTM SSTI, granulomas were more common in specimens from immune-competent patients (18 specimens), whereas deep infiltrates into the subcutaneous tissue, abscess formation, and a foamy appearance of macrophages were more common in specimens from immune-compromised hosts (10 specimens from nine patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356444\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nontuberculous mycobacterial (NTM) skin and soft tissue infection (SSTI) requires isolation of a clinically significant NTM species in culture of biopsy, drainage, or aspirate of fluid from skin nodule, wound, or abscess in a child with compatible clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231497480\">",
"    <span class=\"h2\">",
"     Clinical suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features that should prompt consideration of nontuberculous mycobacteria in children with SSTI include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of water exposure (eg, swimming pool, aquariums, natural bodies of water, etc)",
"     </li>",
"     <li>",
"      History of penetrating injury, surgical procedure, or injection",
"     </li>",
"     <li>",
"      Negative routine bacterial cultures (if performed)",
"     </li>",
"     <li>",
"      Lack of response to",
"      <span class=\"nowrap\">",
"       antistaphylococcal/antistreptococcal",
"      </span>",
"      antibiotics (if administered)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A positive (&ge;5 mm induration)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) can support the diagnosis of NTM infection in children without risk factors for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/43,49\">",
"     43,49",
"    </a>",
"    ]. However, a positive TST cannot distinguish between NTM and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    . Nor does a negative (&lt;5 mm induration) TST exclude mycobacterial disease. (See",
"    <a class=\"local\" href=\"#H1060356451\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link&amp;anchor=H11#H11\">",
"     \"Tuberculosis disease in children\", section on 'Tuberculin skin test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231497487\">",
"    <span class=\"h2\">",
"     Microbiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of NTM SSTI is made by isolation of NTM in culture of biopsy, drainage, or aspirate of fluid from a skin nodule, wound, or abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"     2",
"    </a>",
"    ]. Culture is essential to differentiate NTM from",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , determine which species of NTM is causing infection, and perform susceptibility testing.",
"   </p>",
"   <p>",
"    It is helpful to discuss specimen collection, transport, and culture processing with the microbiology laboratory before sending tissue or fluid to the laboratory if nontuberculous mycobacterial (NTM) infection is suspected. Some species of NTM (eg,",
"    <em>",
"     M. haemophilum",
"    </em>",
"    ) have fastidious growth requirements. Microbiologic techniques to maximize the yield of NTM cultures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive acid-fast staining supports the diagnosis of mycobacterial disease and increases the likelihood of that the isolate is clinically significant, but does not distinguish between NTM and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/11\">",
"     11",
"    </a>",
"    ]. The finding of acid-fast bacilli in routine bacterial culture also supports the diagnosis of NTM (and is suggestive of a rapidly growing species, such as",
"    <em>",
"     M. fortuitum, M. abscessus,",
"    </em>",
"    and",
"    <em>",
"     M. chelonae)",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/59\">",
"     59",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1510068134\">",
"    <span class=\"h3\">",
"     Species identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate antimycobacterial treatment of NTM SSTI requires NTM speciation because different species require different treatments. (See",
"    <a class=\"local\" href=\"#H1261211787\">",
"     'Specific therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rapid methods for identification of NTM species from culture include high-pressure liquid chromatography (HPLC) and polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"     2",
"    </a>",
"    ]. HPLC examines the mycolic acid fingerprint patterns that differ among most species or complexes of mycobacteria and can be used to speciate NTM, including rapidly growing mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/60\">",
"     60",
"    </a>",
"    ]. HPLC cannot reliably differentiate between",
"    <em>",
"     M. abscessus",
"    </em>",
"    and",
"    <em>",
"     M. chelonae",
"    </em>",
"    . The role of PCR in the diagnosis of cutaneous NTM disease is unclear. PCR can differentiate between",
"    <em>",
"     M. abscessus",
"    </em>",
"    and",
"    <em>",
"     M. chelonae",
"    </em>",
"    , and has been used to make the diagnosis of NTM SSTI in a few cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/61\">",
"     61",
"    </a>",
"    ]. However, the variety of species causing cutaneous NTM disease and the need for drug susceptibility testing limits the utility of PCR.",
"   </p>",
"   <p>",
"    The identification of",
"    <em>",
"     M. abscessus",
"    </em>",
"    ,",
"    <em>",
"     M. chelonae",
"    </em>",
"    , and",
"    <em>",
"     M. fortuitum",
"    </em>",
"    may be facilitated by susceptibility testing for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    , sulfamethoxazole, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"     tobramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1261211787\">",
"     'Specific therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762312486\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;When NTM is isolated from a child with SSTI, the clinical significance of the isolate must be determined. The pathogenicity of the various NTM species varies substantially. The possibility that NTM was isolated as a result of contamination also must be considered because NTM is ubiquitous in the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"     2",
"    </a>",
"    ]. Factors that increase the likelihood that the isolate is clinically significant include recovery from multiple specimens and recovery in large quantities (ie, sufficient to result in AFB positive smears).",
"   </p>",
"   <p>",
"    Consultation with a specialist in infectious diseases may be helpful in determining the clinical significance of the isolate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356451\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indolent, chronic, and generally nontender lesions of nontuberculous mycobacterial (NTM) cutaneous disease can mimic those of a number of other cutaneous disorders. Histopathology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microbiology generally are necessary to differentiate between cutaneous NTM and other conditions in the differential diagnosis including [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/50\">",
"     50",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporotrichosis (",
"      <a class=\"graphic graphic_picture graphicRef50115 graphicRef74515 \" href=\"UTD.htm?29/63/30713\">",
"       picture 4A-B",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features and diagnosis of sporotrichosis\", section on 'Lymphocutaneous sporotrichosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nocardiosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and diagnosis of nocardiosis\", section on 'Cutaneous'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cutaneous leishmaniasis (",
"      <a class=\"graphic graphic_picture graphicRef64620 \" href=\"UTD.htm?24/2/24608\">",
"       picture 5",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef65877 \" href=\"UTD.htm?40/16/41231\">",
"       picture 6",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=see_link\">",
"       \"Cutaneous manifestations of tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In immunocompromised hosts, disseminated fungal disease also must be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspergillosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H625354468#H625354468\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Cutaneous aspergillosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cryptococcal disease (",
"      <a class=\"graphic graphic_picture graphicRef69214 \" href=\"UTD.htm?34/15/35058\">",
"       picture 7",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link&amp;anchor=H26#H26\">",
"       \"Cryptococcal infection outside the central nervous system\", section on 'Nonmeningeal, nonpulmonary cryptococcosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Histoplasmosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\", section on 'Skin involvement'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356458\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1510068244\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of nontuberculous mycobacterial (NTM) skin and soft tissue infection (SSTI) in children often requires a combination of surgical and medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consultation with a specialist in infectious diseases may be warranted, particularly when rapidly growing NTM (eg,",
"    <em>",
"     M. fortuitum, M. abscessus, M. chelonae)",
"    </em>",
"    are isolated. No randomized controlled trials or comparative observational studies have evaluated the efficacy of treatments for NTM SSTI. The treatment recommendations below are based upon case series, in vitro susceptibility testing, and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/62-68\">",
"     62-68",
"    </a>",
"    ]. Our recommendations are generally consistent with the 2007 American Thoracic Society and the Infectious Diseases Society of America",
"    <span class=\"nowrap\">",
"     (ATS/IDSA)",
"    </span>",
"    guidelines on the management of nontuberculous mycobacterial diseases and the American Academy of Pediatrics Committee on Infectious Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506956714\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage of abscesses and removal of indwelling foreign bodies, such as intravenous catheters, are essential components of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,45,69\">",
"     2,45,69",
"    </a>",
"    ]. In addition, surgical debridement is optimal for serious localized disease (eg, those with ulceration, deep soft tissue infections, device associated SSTI, and SSTI associated with osteomyelitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231497809\">",
"    <span class=\"h2\">",
"     Antimycobacterial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1261211780\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with NTM SSTI be treated with antimicrobial therapy rather than observation. In observational studies, spontaneous resolution took as long as 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/27,70,71\">",
"     27,70,71",
"    </a>",
"    ]. Antibiotic therapy may hasten resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pending NTM speciation, we suggest that children with localized, nonulcerated NTM SSTI be treated based upon the likely species causing the disease, with a macrolide (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    )",
"    <strong>",
"     plus",
"    </strong>",
"    one of the following (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluoroquinolone (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (for children &ge;8 years old), or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the initial empiric regimen may vary depending upon host factors, suspected species of NTM, and the severity of cutaneous disease. Inclusion of parenterally administered antimicrobial agent(s) in the empiric regimen may be warranted if the patient is immune compromised or if",
"    <em>",
"     M.",
"     <span class=\"nowrap\">",
"      abscessus/M.",
"     </span>",
"     chelonae",
"    </em>",
"    is suspected (on the basis of high-pressure liquid chromatography testing, which cannot differentiate between the two species). Some experts recommend initial parenteral therapy for serious disease (eg, ulceration, deep soft tissue infection, device associated SSTI, and SSTI associated with osteomyelitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/8\">",
"     8",
"    </a>",
"    ]. The suggested initial therapy for serious NTM cutaneous disease varies according to the suspected species [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <em>",
"       M. fortuitum",
"      </em>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       Amikacin",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"     </li>",
"     <li>",
"      <em>",
"       M. abscessus",
"      </em>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"       cefoxitin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"     </li>",
"     <li>",
"      <em>",
"       M. chelonae",
"      </em>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"       tobramycin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolates of rapidly growing mycobacteria (",
"    <em>",
"     M. abscessus, M. chelonae, M. fortuitum",
"    </em>",
"    ) should be tested in vitro against antimicrobials including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    to which they are often susceptible and for which therapeutic response has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Based on in vitro susceptibility testing, a two-drug regimen that includes a macrolide will provide coverage for the most common causes of NTM SSTI in children (",
"    <em>",
"     M. fortuitum, M. abscessus, M. chelonae,",
"    </em>",
"    and",
"    <em>",
"     M. marinum)",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,62-64,72,73\">",
"     2,62-64,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1261211787\">",
"    <span class=\"h3\">",
"     Specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with NTM SSTI in whom a particular species has been isolated, we suggest combination therapy with",
"    <strong>",
"     two",
"    </strong>",
"    drugs to which the isolate is susceptible. However, in vitro susceptibility testing does not always correlate with clinical response and the antimicrobial regimen may need to be changed if the child fails to improve after four to six weeks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       <em>",
"        M. fortuitum",
"       </em>",
"      </strong>",
"      typically is susceptible to macrolides,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      , carbapenems, fluoroquinolones, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,62-64,72-74\">",
"       2,62-64,72-74",
"      </a>",
"      ]. Single-agent therapy with a macrolide is not recommended because",
"      <em>",
"       M. fortuitum",
"      </em>",
"      has inducible macrolide resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H18#H18\">",
"       \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Susceptibility patterns'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       <em>",
"        M. abscessus",
"       </em>",
"      </strong>",
"      typically is susceptible to macrolides,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"       cefoxitin",
"      </a>",
"      , or a carbapenem (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/63,64,72-74\">",
"       63,64,72-74",
"      </a>",
"      ]. Single-agent therapy with a macrolide is not recommended because",
"      <em>",
"       M. abscessus",
"      </em>",
"      has inducible macrolide resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H18#H18\">",
"       \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Susceptibility patterns'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       <em>",
"        M. chelonae",
"       </em>",
"      </strong>",
"      typically is susceptible to macrolides,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"       tobramycin",
"      </a>",
"      , and carbapenems (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/62-64,72-74\">",
"       62-64,72-74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Susceptibility testing generally is not performed for",
"      <strong>",
"       <em>",
"        M. marinum",
"       </em>",
"      </strong>",
"      isolates unless the patient fails to improve after several months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <em>",
"       M. marinum",
"      </em>",
"      typically is susceptible to rifamycins (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"       rifabutin",
"      </a>",
"      ),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       ethambutol",
"      </a>",
"      , macrolides, and TMP-SMX (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2,8\">",
"       2,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment for",
"      <strong>",
"       <em>",
"        M. ulcerans",
"       </em>",
"      </strong>",
"      is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39033?source=see_link&amp;anchor=H8#H8\">",
"       \"Buruli ulcer (Mycobacterium ulcerans infection)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2473623173\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimycobacterial agents that are used to treat NTM SSTI often are difficult to tolerate and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    , optic neuropathy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and hepatotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    . The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link\">",
"     \"Azithromycin, clarithromycin, and telithromycin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link\">",
"     \"Isoniazid: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1261211868\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;NTM SSTI in immune-competent children with isolated cutaneous lesions is usually continued for one to two months after symptom resolution (usually for a total of three to four months) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060356465\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy for NTM skin and soft tissue infections is monitored clinically. We suggest follow-up visits at approximately monthly intervals to ensure that patients are taking and tolerating their medications and that their skin lesions are improving.",
"   </p>",
"   <p>",
"    Alternative diagnoses should be considered in patients who have no response to therapy after four to six weeks. At this point, if there is culture-confirmation, it is important to ask about adherence to antimycobacterial therapy and potential for medication malabsorption (eg, vomiting, diarrhea, concurrent administration of other medications that may decrease serum levels of antimycobacterial therapy).",
"   </p>",
"   <p>",
"    For patients without definitive microbiologic data who are not improving or are worsening after four to six weeks of antimycobacterial therapy, surgical consultation may be warranted for debridement and to obtain specimens for cultures and histopathology.",
"   </p>",
"   <p>",
"    The addition of treatment with antistreptococcal and antistaphylococcal antibiotics also may be warranted to address the possibility of pyogenic superinfection contributing to worsening. When adding agents to an antimycobacterial regimen, it is important to add two drugs (eg, a quinolone and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) to the failing regimen; adding a single drug may predispose to the development of resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1510069391\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the prevention of nontuberculous mycobacterial skin and soft tissue infections in children include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoiding the use of benzalkonium chloride as a skin disinfectant because it allows the growth of mycobacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?7/34/7722/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Avoiding alternative medicine practices that involve the injection of unknown or unapproved substances",
"     </li>",
"     <li>",
"      In hospitalized patients, avoiding washing or contaminating open wounds with tap water",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060357426\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of nontuberculous mycobacterial (NTM) skin and soft tissue infections (SSTI) in children include rapidly growing NTM species (",
"      <em>",
"       Mycobacterium fortuitum, M. abscessus,",
"      </em>",
"      and",
"      <em>",
"       M. chelonae), M. marinum,",
"      </em>",
"      and",
"      <em>",
"       M. ulcerans.",
"      </em>",
"      (See",
"      <a class=\"local\" href=\"#H1060356416\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin abrasions and penetrating trauma are the usual portals of entry for NTM SSTI. The incubation period is variable, but usually is between three and four weeks. (See",
"      <a class=\"local\" href=\"#H1060356423\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NTM SSTI may occur as an isolated finding in immune-competent children or as part of the clinical spectrum of disseminated disease in immune-compromised patients. NTM SSTI typically follow cutaneous trauma in swimming pools, aquariums, or natural bodies of water. Nosocomial infection may occur at the site of surgery, vascular catheters, or injections. (See",
"      <a class=\"local\" href=\"#H1060356430\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous NTM infections are polymorphous. Ulcerations (",
"      <a class=\"graphic graphic_picture graphicRef68569 \" href=\"UTD.htm?27/63/28658\">",
"       picture 2",
"      </a>",
"      ), plaques, folliculitis, indurated erythematous papules, and nodules (",
"      <a class=\"graphic graphic_picture graphicRef81640 \" href=\"UTD.htm?5/19/5425\">",
"       picture 3",
"      </a>",
"      ) have been described. (See",
"      <a class=\"local\" href=\"#H1060356430\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of NTM SSTI requires isolation of a clinically significant NTM species in culture of biopsy, drainage, or aspirate of fluid from skin nodule, wound, or abscess in a child with compatible clinical findings. Clinical features that should prompt consideration of NTM in a child with SSTI include history of water exposure, penetrating injury, surgical procedure, or injection; negative bacterial cultures (if performed); lack of response to",
"      <span class=\"nowrap\">",
"       antistaphylococcal/antistreptococcal",
"      </span>",
"      antibiotics (if administered), and isolation of acid-fast bacilli in routine bacterial culture. (See",
"      <a class=\"local\" href=\"#H1060356444\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of NTM SSTI may require a combination of surgical and medical therapy. Drainage of abscesses and removal of foreign bodies (if present) are essential components of treatment. In addition, surgical debridement is optimal for serious localized disease. (See",
"      <a class=\"local\" href=\"#H506956714\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with NTM SSTI be treated with antimycobacterial therapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Spontaneous resolution may take up to 12 months. (See",
"      <a class=\"local\" href=\"#H1231497809\">",
"       'Antimycobacterial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pending speciation, we suggest that children with localized, nonulcerated NTM SSTI be treated with a macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      )",
"      <strong>",
"       plus",
"      </strong>",
"      one of the following: a fluoroquinolone,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"       doxycycline",
"      </a>",
"      (for children &ge;8 years), or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Parenterally administered antimicrobial agent(s) (including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"       cefoxitin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      ) may be warranted for serious disease (eg, ulceration, deep soft tissue infections, device associated SSTI, and SSTI associated with osteomyelitis), immune compromised hosts, or if",
"      <em>",
"       M.",
"       <span class=\"nowrap\">",
"        abscessus/M.",
"       </span>",
"       chelonae",
"      </em>",
"      is suspected. Once the species is identified, we suggest that the child be treated with two drugs to which the isolate is susceptible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1261211780\">",
"       'Empiric therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1261211787\">",
"       'Specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy is continued for one to two months after symptom resolution (usually for a total of three to four months). (See",
"      <a class=\"local\" href=\"#H1261211868\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/1\">",
"      Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/2\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/3\">",
"      Celdr&aacute;n A, Esteban J, Ma&ntilde;as J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/4\">",
"      Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/5\">",
"      Al Soub H, Al Maslamani M, Al Khuwaiter J, et al. Myocardial abscess and bacteremia complicating Mycobacterium fortuitum pacemaker infection: case report and review of the literature. Pediatr Infect Dis J 2009; 28:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/6\">",
"      McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/7\">",
"      Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Diseases caused by nontuberculous mycobacteria: (atypical mycobacteria, mycobacteria other than Mycobacterium tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.759.",
"    </li>",
"    <li>",
"     Mycobacterium. In: List of Prokaryotic names with Standing in Nomenclature. file://www.bacterio.cict.fr/m/mycobacterium.html (Accessed on July 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/10\">",
"      Bartralot R, Pujol RM, Garc&iacute;a-Patos V, et al. Cutaneous infections due to nontuberculous mycobacteria: histopathological review of 28 cases. Comparative study between lesions observed in immunosuppressed patients and normal hosts. J Cutan Pathol 2000; 27:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/11\">",
"      Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/12\">",
"      Chen HY, Chen CY, Huang CT, et al. Skin and soft-tissue infection caused by non-tuberculous mycobacteria in Taiwan, 1997-2008. Epidemiol Infect 2011; 139:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/13\">",
"      Mahaisavariya P, Chaiprasert A, Khemngern S, et al. Nontuberculous mycobacterial skin infections: clinical and bacteriological studies. J Med Assoc Thai 2003; 86:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/14\">",
"      Wentworth AB, Drage LA, Wengenack NL, et al. Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population-based study. Mayo Clin Proc 2013; 88:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/15\">",
"      Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/16\">",
"      Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998; 52:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/17\">",
"      Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/18\">",
"      Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/19\">",
"      Pham-Huy A, Robinson JL, Tapi&eacute;ro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/20\">",
"      Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/21\">",
"      Mangione EJ, Huitt G, Lenaway D, et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis 2001; 7:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/22\">",
"      Fleming GA, Frangoul H, Dermody TS, Halasa N. A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. Pediatr Infect Dis J 2006; 25:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/23\">",
"      Livni G, Yaniv I, Samra Z, et al. Outbreak of Mycobacterium mucogenicum bacteraemia due to contaminated water supply in a paediatric haematology-oncology department. J Hosp Infect 2008; 70:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/24\">",
"      Shachor-Meyouhas Y, Sprecher H, Eluk O, et al. An outbreak of Mycobacterium mucogenicum bacteremia in pediatric hematology-oncology patients. Pediatr Infect Dis J 2011; 30:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/25\">",
"      Falkinham JO 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011; 17:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/26\">",
"      Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/27\">",
"      Escalonilla P, Esteban J, Soriano ML, et al. Cutaneous manifestations of infection by nontuberculous mycobacteria. Clin Exp Dermatol 1998; 23:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/28\">",
"      Kelly SE. Multiple injection abscesses in a diabetic caused by Mycobacterium chelonei. Clin Exp Dermatol 1987; 12:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/29\">",
"      Tang P, Walsh S, Murray C, et al. Outbreak of acupuncture-associated cutaneous Mycobacterium abscessus infections. J Cutan Med Surg 2006; 10:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/30\">",
"      Zhibang Y, BiXia Z, Qishan L, et al. Large-scale outbreak of infection with Mycobacterium chelonae subsp. abscessus after penicillin injection. J Clin Microbiol 2002; 40:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/31\">",
"      Castro-Silva AN, Freire AO, Grinbaum RS, et al. Cutaneous Mycobacterium haemophilum infection in a kidney transplant recipient after acupuncture treatment. Transpl Infect Dis 2011; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/32\">",
"      Horii KA, Jackson MA. Images in clinical medicine. Piercing-related nontuberculous mycobacterial infection. N Engl J Med 2010; 362:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/33\">",
"      Ferringer T, Pride H, Tyler W. Body piercing complicated by atypical mycobacterial infections. Pediatr Dermatol 2008; 25:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/34\">",
"      Kennedy BS, Bedard B, Younge M, et al. Outbreak of Mycobacterium chelonae infection associated with tattoo ink. N Engl J Med 2012; 367:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Tattoo-associated nontuberculous mycobacterial skin infections--multiple states, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/36\">",
"      Dytoc MT, Honish L, Shandro C, et al. Clinical, microbiological, and epidemiological findings of an outbreak of Mycobacterium abscessus hand-and-foot disease. Diagn Microbiol Infect Dis 2005; 53:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/37\">",
"      Camargo D, Saad C, Ruiz F, et al. Iatrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect 1996; 117:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/38\">",
"      Winthrop KL, Abrams M, Yakrus M, et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med 2002; 346:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/39\">",
"      Jernigan JA, Farr BM. Incubation period and sources of exposure for cutaneous Mycobacterium marinum infection: case report and review of the literature. Clin Infect Dis 2000; 31:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/40\">",
"      Parent LJ, Salam MM, Appelbaum PC, Dossett JH. Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency. Clin Infect Dis 1995; 21:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/41\">",
"      Friedman BF, Edwards D, Kirkpatrick CH. Mycobacterium avium-intracellulare: cutaneous presentations of disseminated disease. Am J Med 1988; 85:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/42\">",
"      Hanke CW, Temofeew RK, Slama SL. Mycobacterium kansasii infection with multiple cutaneous lesions. J Am Acad Dermatol 1987; 16:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/43\">",
"      Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 2003; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/44\">",
"      Casal M, Casal MM, Spanish Group of Mycobacteriology. Multicenter study of incidence of Mycobacterium marinum in humans in Spain. Int J Tuberc Lung Dis 2001; 5:197.",
"     </a>",
"    </li>",
"    <li>",
"     Tebruegge M, Curtis N. Mycobacterium species non-tuberculosis. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.786.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/46\">",
"      Dodiuk-Gad R, Dyachenko P, Ziv M, et al. Nontuberculous mycobacterial infections of the skin: A retrospective study of 25 cases. J Am Acad Dermatol 2007; 57:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/47\">",
"      Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 2009; 15:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/48\">",
"      Edson RS, Terrell CL, Brutinel WM, Wengenack NL. Mycobacterium intermedium granulomatous dermatitis from hot tub exposure. Emerg Infect Dis 2006; 12:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/49\">",
"      Haimi-Cohen Y, Amir J, Eidlitz-Markus T, et al. Chronic cheek lesions: an unusual manifestation of nontuberculous mycobacterial cevicofacial infection. J Pediatr 2009; 155:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/50\">",
"      Bartralot R, Garc&iacute;a-Patos V, Sitjas D, et al. Clinical patterns of cutaneous nontuberculous mycobacterial infections. Br J Dermatol 2005; 152:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/51\">",
"      Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/52\">",
"      Subbarao EK, Tarpay MM, Marks MI. Soft-tissue infections caused by Mycobacterium fortuitum complex following penetrating injury. Am J Dis Child 1987; 141:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/53\">",
"      Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med 1994; 154:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/54\">",
"      Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/55\">",
"      Uslan DZ, Kowalski TJ, Wengenack NL, et al. Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol 2006; 142:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/56\">",
"      Van Seymortier P, Verellen K, De Jonge I. Mycobacterium marinum causing tenosynovitis. 'Fish tank finger'. Acta Orthop Belg 2004; 70:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/57\">",
"      Chan ED, Kong PM, Fennelly K, et al. Vertebral osteomyelitis due to infection with nontuberculous Mycobacterium species after blunt trauma to the back: 3 examples of the principle of locus minoris resistentiae. Clin Infect Dis 2001; 32:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/58\">",
"      Song H, Lee H, Choi G, Shin J. Cutaneous nontuberculous mycobacterial infection: a clinicopathological study of 7 cases. Am J Dermatopathol 2009; 31:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/59\">",
"      Elston D. Nontuberculous mycobacterial skin infections: recognition and management. Am J Clin Dermatol 2009; 10:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/60\">",
"      Butler WR, Ahearn DG, Kilburn JO. High-performance liquid chromatography of mycolic acids as a tool in the identification of Corynebacterium, Nocardia, Rhodococcus, and Mycobacterium species. J Clin Microbiol 1986; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/61\">",
"      Collina G, Morandi L, Lanzoni A, Reggiani M. Atypical cutaneous mycobacteriosis diagnosed by polymerase chain reaction. Br J Dermatol 2002; 147:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/62\">",
"      Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/63\">",
"      Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/64\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/65\">",
"      Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/66\">",
"      Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/67\">",
"      Khardori N, Nguyen H, Rosenbaum B, et al. In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents. Antimicrob Agents Chemother 1994; 38:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/68\">",
"      Kuhn SM, Rosen W, Wong A, Jadavji T. Treatment of Mycobacterium marinum facial abscess using clarithromycin. Pediatr Infect Dis J 1995; 14:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/69\">",
"      Esteban J, Fern&aacute;ndez Roblas R, Garc&iacute;a C&iacute;a JI, et al. Clinical significance and epidemiology of non-pigmented rapidly growing mycobacteria in a university hospital. J Infect 2007; 54:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/70\">",
"      Winthrop KL, Albridge K, South D, et al. The clinical management and outcome of nail salon-acquired Mycobacterium fortuitum skin infection. Clin Infect Dis 2004; 38:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/71\">",
"      Woods GL, Washington JA 2nd. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 1987; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/72\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/73\">",
"      Wallace RJ Jr, Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/74\">",
"      Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/75\">",
"      Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/76\">",
"      Tiwari TS, Ray B, Jost KC Jr, et al. Forty years of disinfectant failure: outbreak of postinjection Mycobacterium abscessus infection caused by contamination of benzalkonium chloride. Clin Infect Dis 2003; 36:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/34/7722/abstract/77\">",
"      Rikimaru T, Kondo M, Kondo S, Oizumi K. Efficacy of common antiseptics against mycobacteria. Int J Tuberc Lung Dis 2000; 4:570.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85895 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7722=[""].join("\n");
var outline_f7_34_7722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1060357426\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356409\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356416\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356423\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356430\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1510067549\">",
"      General features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1510067648\">",
"      Rapidly growing NTM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231497626\">",
"      M. marinum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231497680\">",
"      M. ulcerans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231497649\">",
"      Immune-compromised host",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231497657\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356437\">",
"      HISTOPATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356444\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231497480\">",
"      Clinical suspicion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231497487\">",
"      Microbiologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1510068134\">",
"      - Species identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1762312486\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356451\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356458\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1510068244\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H506956714\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231497809\">",
"      Antimycobacterial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1261211780\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1261211787\">",
"      - Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2473623173\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1261211868\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060356465\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1510069391\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060357426\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/85895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85895|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/46/36581\" title=\"picture 1\">",
"      Disseminated NTM skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/63/28658\" title=\"picture 2\">",
"      Mycobacterium marinum nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/19/5425\" title=\"picture 3\">",
"      Fish tank granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/31/12788\" title=\"picture 4A\">",
"      Lymphocutaneous sporotrichosis arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/59/7094\" title=\"picture 4B\">",
"      Fixed cutaneous sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/2/24608\" title=\"picture 5\">",
"      New World CL ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/16/41231\" title=\"picture 6\">",
"      Metastatic tuberculous abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/15/35058\" title=\"picture 7\">",
"      Disseminated cryptococcosis - papules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85895|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/4/8271\" title=\"table 2\">",
"      Treatment NTM children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39033?source=related_link\">",
"      Buruli ulcer (Mycobacterium ulcerans infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=related_link\">",
"      Cutaneous manifestations of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39401?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20550?source=related_link\">",
"      Infectious tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=related_link\">",
"      Lymphangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=related_link\">",
"      Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/282?source=related_link\">",
"      Overview of nontuberculous mycobacterial pulmonary infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=related_link\">",
"      Pathogenesis of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=related_link\">",
"      Rapidly growing mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/39/13946?source=related_link\">",
"      Treatment of osteomyelitis due to nontuberculous mycobacteria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_34_7723="Minimizing exercise test risk";
var content_f7_34_7723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimizing the risks of exercise testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Trained personnel (testing, treatment, CPR expertise, etc.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physician or other health care professional in attendance during testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuous ECG monitoring during and after testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pretest history and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resting ECG interpretation before exercise begins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient awareness of limiting signs and symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency resuscitation equipment and drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Attention to exercise test end points&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No shower until cool-down finished",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7723=[""].join("\n");
var outline_f7_34_7723=null;
var title_f7_34_7724="Etiologies of neonatal seizures";
var content_f7_34_7724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most frequently occurring etiologies of neonatal seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Neonatal and hypoxic-ischemic encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intraventricular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intracerebral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subdural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subarachnoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Central nervous system infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intrauterine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypocalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromosomal anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital abnormalities of the brain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurodegenerative disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inborn errors of metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign neonatal convulsions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign familial neonatal convulsions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug withdrawal or intoxication",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Listed in relative order of frequency. Not listed is \"unknown\" etiology, which is encountered in approximately 10 percent of cases (although some in this category may be benign neonatal convulsions).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mizrahi EM, Kellaway P. Diagnosis and Management of Neonatal Seizures. Lippincott-Raven, Philadelphia 1998. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7724=[""].join("\n");
var outline_f7_34_7724=null;
var title_f7_34_7725="Radiation biodosimetry";
var content_f7_34_7725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiation biodosimetry",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Dose (Gy)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vomiting (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to vomiting (hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        ALC day 1*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lymphocyte fall rate constant (k)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lymphocyte dicentrics (per 1000)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        2450",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        2160",
"       </td>",
"       <td>",
"        0.126",
"       </td>",
"       <td>",
"        88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        1900",
"       </td>",
"       <td>",
"        0.252",
"       </td>",
"       <td>",
"        234",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        1680",
"       </td>",
"       <td>",
"        0.378",
"       </td>",
"       <td>",
"        439",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        1480",
"       </td>",
"       <td>",
"        0.504",
"       </td>",
"       <td>",
"        703",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        1310",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        1150",
"       </td>",
"       <td>",
"        0.756",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        1010",
"       </td>",
"       <td>",
"        0.881",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        890",
"       </td>",
"       <td>",
"        1.01",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        790",
"       </td>",
"       <td>",
"        1.13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        700",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Gy: absorbed whole body dose in Grey units.",
"     <br>",
"      * ALC day 1: absolute lymphocyte count per microL on day 1 after exposure.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       The lymphocyte fall rate constant is derived from a semilogarithmic plot of the absolute lymphocyte count (ALC) versus time in days, in the form of 2450 x e",
"       <sup>",
"        -kt",
"       </sup>",
"       . The time (in days) for the ALC to fall to one-half of its original value [half-time, T(1/2)] can be obtained from the following equation: T(1/2) = 0.693/k.",
"       <br>",
"        &Delta; Dicentric chromosomes are those containing two separate centromeres, caused by end-to-end recombination of two damaged chromosomes.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Int Med 2004; 140:1039. Copyright &copy; 2004 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7725=[""].join("\n");
var outline_f7_34_7725=null;
var title_f7_34_7726="Outcome recurrent cervical CA";
var content_f7_34_7726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm showing theoretical outcome for patients diagnosed with recurrent cervical cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7726=[""].join("\n");
var outline_f7_34_7726=null;
var title_f7_34_7727="Ulcerogenesis with H pylori";
var content_f7_34_7727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Possible mechanisms of ulcerogenesis in Helicobacter pylori infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 440px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American College of Gastroenterology, American Journal of Gastroenterology, 1997; 92:11S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_34_7727=[""].join("\n");
var outline_f7_34_7727=null;
